Asymmetric Benzylic C(sp³)–H Acylation via Dual Nickel and Photoredox Catalysis

Leitao Huan, Xiaomin Shu, Weisai Zu, De Zhong, and Haohua Huo*

State Key Laboratory of Physical Chemistry of Solid Surfaces, Key Laboratory of Chemical Biology of Fujian Province, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, P. R. China

Supplementary Information

Table of Contents

I.	General Information	S-2
II.	Effect of Reaction Parameters	S-3
III.	Catalytic Enantioselective Benzylic C(sp ³)–H Acylation	S-5
IV.	Synthetic Utility: Gram Scale Synthesis and Parallel Synthesis	S-40
V.	Mechanistic Studies	S-48
VI.	Assignment of Absolute Configuration	S-54
VII.	¹ H-NMR and ¹³ C-NMR Spectra; Stereoselectivity Analysis	S-57
VIII.	Supplementary References	S-216

I. General Information

Unless otherwise noted, reactions were performed with rigorous exclusion of air and moisture. Anhydrous *i*-PrOAc (>99.6%, Sigma-Aldrich) and EtOAc (99.9%, J&K) were dried using freshly activated 4Å MS and bubbled with argon for 1 h before it was brought into the glovebox. Chiral ligands (>98%, DAICEL), NiBr₂·glyme (>97%, Strem), NH₄Cl (99.99%, Alfa Aesar), Na₂HPO₄ (>99.0%, Sigma-Aldrich), and DMDC (Rhawn), K₂HPO₄ (>99.9%, Sigma-Aldrich), KHCO₃ (>99.9%, Sigma-Aldrich), phenyl carbonochloridate (98%, Energy), and all commercially available carboxylic acids and alkylarenes (Alfa Aesar, Energy Chemical, TCI, and Sigma-Aldrich) were used as received. Alkylarenes for preparation of compounds **26**, **34**, **35**, **41**, **42**, **47**, **50**, **51**, **61-65**, and **53**, were synthesized according to a literature procedure,¹ and all analytical data matched that report.

NMR spectra were collected on a Bruker 400 MHz, a Bruker 500 MHz, a Bruker 600 MHz, or a Varian 500 MHz spectrometer at ambient temperature. HPLC analyses were carried out on an Agilent 1260 series system with Daicel CHIRALPAK® or Daicel CHIRALCEL® columns (4.6 × 250 mm, particle size 3 μ m and 5 μ m). FT-IR measurements were carried out on a Nicolet AVATER FTIR330 spectrometer. High resolution mass spectra (ESI) were recorded by the instrumentation center of Department of Chemistry, Xiamen University, on a high-resolution LC/MS instrument. Optical rotation data were obtained with an Anton Paar MCP 500 polarimeter at 589 nm and at 25 °C, using a 100 mm path-length cell in the solvent and at the concentration indicated. GC analyses were obtained on an Agilent 6890A GC. Flash column chromatography was performed using silica gel (300–400 mesh). Blue LED lamps (40 W; Kessil PR160L) were used to irradiate the reaction mixtures.

II. Effect of Reaction Parameters

General Procedure A (GP-A): In a glovebox, Ir[dF(CF₃)ppy]₂(dtbbpy)PF₆ (1.1 mg, 0.001 mmol, 1%), NiBr₂·glyme (3.1 mg, 0.010 mmol, 10%), (S)-L (4.7 mg, 0.013 mmol, 13%), NH₄Cl (5.3 mg, 0.10 mmol, 1.0 equiv), Na₂HPO₄ (21.3 mg, 0.15 mmol, 1.5 equiv), a Teflon stir bar, and anhydrous *i*-PrOAc (1.0 mL) were added sequentially to a 4-mL vial. The reaction mixture was stirred at room temperature for 30 min, after which it turned to a purple suspension. A solution of the 4ethylbiphenyl (0.15 mL, 2.0 M in *i*-PrOAc, 0.30 mmol, 3.0 equiv) was added via a 0.25 mL syringe. The vial was sealed with a septum cap and wrapped with electrical tape, followed by the sequential addition of 3-phenylpropanoic acid (0.10 mL, 1.0 M in *i*-PrOAc, 0.10 mmol, 1.0 equiv) and DMDC (16.2 µL, 0.15 mmol, 1.5 equiv) via microsyringe. Next, the vial was transferred out of the glovebox, the vacuum grease was liberally applied to cover the entire top of septum cap. Then, the reaction mixture was stirred at 10 °C in an EtOH bath for 5 min before being irradiated with a 40 W blue LED lamp (Kessil PR160L, 427 nm). The reaction was stirred at 10 °C under irradiation for 25 hours. Next, the lamp was turned off and the resulting mixture was allowed to warm to room temperature, and then dodecane (22 µL, 0.10 mmol) was added as an internal standard. The mixture was filtered through a small plug of silica gel, which was flushed with Et₂O (~10 mL). A portion of the filtrate (~0.1 mL) was diluted with acetone (total volume: 1 mL) and analyzed via GC, and the remainder of the filtrate was concentrated via rotary evaporation, and the pure product was isolated by preparative TLC on silica gel (1:30 EtOAc/hexanes).

The results for the effect of reaction parameters were shown in Table 1 and Supplementary Table 1. **GP-A** was followed for the experiments set-up, using 3-phenylpropanoic acid (0.10 mmol) and 4-ethylbiphenyl (0.30 mmol), the yield was determined via GC analysis with dodecane as an internal standard. The ee values were determined via HPLC analysis after purification by preparative thin-layer chromatography.

Supplementary Table 1. Further study of effect of reaction parameters



III. Catalytic Enantioselective Benzylic C(sp³)-H Acylation



Supplementary Methods

Supplementary Figure 1. Exemplary reaction setup (two runs for each substrate)

General Procedure B (GP-B): Catalytic enantioselective acylation of benzylic C(sp³)-H bonds with alkyl carboxylic acids. In a glovebox, Ir[dF(CF₃)ppy]₂(dtbbpy)PF₆ (5.5 mg, 0.005 mmol, 1%), NiBr₂·glyme (15.5 mg, 0.05 mmol, 10%), (S)-L (23.5 mg, 0.065 mmol, 13%), NH₄Cl (26.5 mg, 0.50 mmol, 1.0 equiv), Na₂HPO₄ (106.5 mg, 0.75 mmol, 1.5 equiv), a Teflon stir bar, and anhydrous *i*-PrOAc (5.0 mL) were added sequentially to a 15 mL vial. The reaction mixture was stirred at room temperature for 30 min, after which it turned to a purple suspension. Next, a solution of the alkylarene (0.75 mL, 2.0 M solution in *i*-PrOAc, 1.50 mmol, 3.0 equiv) was added via a 1.0 mL syringe (if the carboxylic acid was a solid, it was added as solid directly at this point following the addition of alkylarene). The vial was closed with a PTFE septum cap and wrapped with electrical tape. Then, carboxylic acid (0.50 mmol, 1.0 equiv) and DMDC (80.0 µL, 0.75 mmol, 1.5 equiv) were added sequentially via microsyringe. Next, the vial was transferred out of the glovebox, and then vacuum grease was liberally applied to cover the entire top of the septum cap. Then, the reaction mixture was stirred at 10 °C in an EtOH bath for 5 min before being irradiated with a 40 W blue LED lamp (Kessil PR160L, 427 nm). The reaction was stirred under irradiation at 10 °C for 25 hours. The reaction mixture was then passed through a short pad of silica gel, with Et₂O as the eluent (~35 mL). The resulting mixture was concentrated, and the residue was purified by chromatography on silica gel.

For compounds **49** and **58**, the procedure is the same as above, but the reaction was conducted at 25°C in dioxane; For compound **56**, the procedure is the same as above, but the reaction was conducted at 25 °C in place of 10 °C; For the compound **57**, in place of the standard conditions, 5.0 equiv of 4-ethylbiphenyl was used; For the compounds **51** and **52**, the reactions were stirred for 15 hours instead of 25 hours.

General Procedure C (GP-C): Catalytic enantioselective acylation of benzylic C(sp³)–H bonds with artesunate. The procedure is the same as GP-B, except for changes in the following quantities: alkylarene (2.5 mmol, 5.0 equiv), and the reaction was stirred for 35 hours.

General Procedure D (GP-D): Catalytic enantioselective acylation of benzylic C(sp³)-H bonds with aromatic carboxylic acids. In a glovebox, Ir[dF(CF₃)ppy]₂(dtbbpy)PF₆ (5.5 mg, 0.005 mmol, 1%), NiBr₂·glyme (15.5 mg, 0.05 mmol, 10%), (S, R)-L3 (20.6 mg, 0.065 mmol, 13%), NH₄Cl (26.5 mg, 0.50 mmol, 1.0 equiv), K₂HPO₄ (261.3 mg, 1.50 mmol, 3.0 equiv), a Teflon stir bar, and anhydrous *i*-PrOAc (5.0 mL) were added sequentially to a 15 mL vial. The reaction mixture was stirred at room temperature for 30 min, after which it turned to a grass green suspension. Next, 4-propyl-1,1'-biphenyl (297 μL, 1.50 mmol, 3.0 equiv) was added via microsyringe, then aromatic carboxylic acids were added directly as a solid. The vial was closed with a PTFE septum cap and wrapped with electrical tape. Then, DMDC (161 µL, 1.50 mmol, 3.0 equiv) were added sequentially via a microsyringe. Next, the vial was transferred out of the glovebox, and then vacuum grease was liberally applied to cover the entire top of the septum cap. Then, the reaction mixture was stirred at 10 °C in an EtOH bath for 5 min before being irradiated with a 40 W blue LED lamp (Kessil PR160L, 427 nm). The reaction was stirred under irradiation at 10 °C for 28 hours. The reaction mixture was then passed through a short pad of silica gel, with Et₂O as the eluent (~35 mL). The resulting mixture was concentrated, and the residue was purified by preparative thin-layer chromatography on silica gel.

General Procedure E (GP-E): Catalytic enantioselective acylation of benzylic C(sp³)–H bonds with phenyl chloroformate. In a glovebox, Ir[dF(CF₃)ppy]₂(dtbbpy)PF₆ (5.5 mg, 0.005 mmol, 1%), NiBr₂·glyme (15.5 mg, 0.05 mmol, 10%), (*S*, *R*)-L2 (49.3 mg, 0.065 mmol, 13%), KHCO₃ (75.1 mg, 0.75 mmol, 1.5 equiv), a Teflon stir bar, and anhydrous EtOAc (5.0 mL) were added sequentially to a 15 mL vial. The reaction mixture was stirred at room temperature for 30 min, after which it turned to a brown red suspension. Next, alkylarene (1.50 mmol, 3.0 equiv) was added via microsyringe. The vial was closed with a PTFE septum cap and wrapped with electrical tape. Then, phenyl chloroformate (63 µL, 0.50 mmol, 1.0 equiv) were added sequentially via a microsyringe. Next, the vial was transferred out of the glovebox, and then vacuum grease was liberally applied to cover the entire top of the septum cap. Then, the reaction mixture was stirred at ~30 °C in an EtOH bath for 5 min before being irradiated with a 40 W blue LED lamp (Kessil PR160L, 427 nm). The reaction was stirred under irradiation at ~30 °C for 40 hours. The reaction mixture was then passed through a short pad of silica gel, with Et₂O as the eluent (~35 mL). The resulting mixture was concentrated, and the residue was purified by preparative thin-layer chromatography on silica gel.



4-([1,1'-Biphenyl]-4-yl)-1-phenylpentan-3-one (Fig. 2, compound 1). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:80 EtOAc/Petroleum ether). White solid (mp = 84-85 °C).

(*S*)-L: 127 mg, 81% yield, 94% ee; (*R*)-L: 130 mg, 83% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 6.6 min (major), 6.9 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, *J* = 7.7 Hz, 2H), 7.51 (d, *J* = 8.0 Hz, 2H), 7.42 (t, *J* = 7.4 Hz, 2H), 7.33 (t, *J* = 7.4 Hz, 1H), 7.22 – 7.19 (m, 4H), 7.16 – 7.12 (m, 1H), 7.06 (d, *J* = 7.4 Hz, 2H), 3.74 (q, *J* = 6.9 Hz, 1H), 2.90 – 2.63 (m, 4H), 1.40 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 209.7, 141.0, 140.6, 140.0, 139.4, 128.7, 128.3, 128.25, 128.23, 127.6, 127.3, 127.0, 126.0, 52.8, 42.6, 29.9, 17.3.

FT-IR (film): 2921, 1705, 1485, 1452, 1196, 1180, 1141, 1075, 838, 759, 697 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₃H₂₂ONa: 337.1563, found: 337.1558.

 $[\alpha]^{25}$ _D = +101.2 (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



3-([1,1'-Biphenyl]-4-yl)butan-2-one (Fig. 2, compound 2). The title compound was synthesized according to **GP-B** from acetic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:150 EtOAc/Petroleum ether). White solid (mp = 69-70 °C).

(S)-L: 98 mg, 88% yield, 95% ee; (R)-L: 99 mg, 88% yield, 95% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.8 min (minor), 9.3 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.62 – 7.57 (m, 4H), 7.48 – 7.43 (m, 2H), 7.38 – 7.34 (m, 1H), 7.33 – 7.30 (m, 2H), 3.81 (q, *J* = 7.0 Hz, 1H), 2.11 (s, 3H), 1.46 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 208.6, 140.5, 140.0, 139.5, 128.7, 128.2, 127.6, 127.3, 126.9, 53.3, 28.4, 17.2.

FT-IR (film): 2977, 2931, 1705, 1581, 1450, 1353, 1165, 754, 725, 688 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₆H₁₆ONa: 247.1093, found: 247.1090.

 $[\alpha]^{25}$ _D = +212.8 (*c* 1.0, CH₂Cl₂); 95% ee from (*S*)-L.



2-([1,1'-Biphenyl]-4-yl)hexan-3-one (Fig. 2, compound 3). The title compound was synthesized according to **GP-B** from butyric acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:400 EtOAc/Petroleum ether). White solid (mp = 34-36 °C).

(*S*)-L: 111 mg, 88% yield, 94% ee; (*R*)-L: 111 mg, 88% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 7.0 min (minor), 8.8 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.61 – 7.56 (m, 4H), 7.47 – 7.43 (m, 2H), 7.37 – 7.33 (m, 1H), 7.32 – 7.29 (m, 2H), 3.81 (q, *J* = 7.0 Hz, 1H), 2.41 – 2.37 (m, 2H), 1.63-1.49 (m, 2H), 1.44 (d, *J* = 7.0 Hz, 3H), 0.84 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 210.8, 140.6, 140.0, 139.7, 128.7, 128.2, 127.5, 127.3, 127.0, 52.5, 43.0, 17.4, 17.2, 13.6.

FT-IR (film): 2976, 2931, 2874, 1712, 1487, 1451, 1136, 763, 726 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₈H₂₀ONa: 275.1406, found: 275.1403.

 $[\alpha]^{25_{\rm D}} = -195.4$ (*c* 1.0, CH₂Cl₂); 94% ee from (*R*)-L.



2-([1,1'-Biphenyl]-4-yl)undecan-3-one (Fig. 2, compound 4). The title compound was synthesized according to **GP-B** from nonanoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:400 EtOAc/Petroleum ether). White solid (mp = 62-63 °C).

(*S*)-L: 141 mg, 87% yield, 93% ee; (*R*)-L: 137 mg, 85% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 4.5 min (minor), 5.2 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.60 – 7.55 (m, 4H), 7.46 – 7.42 (m, 2H), 7.37 – 7.33 (m, 1H), 7.31 – 7.28 (m, 2H), 3.81 (q, *J* = 7.0 Hz, 1H), 2.44 – 2.34 (m, 2H), 1.54 – 1.49 (m, 2H), 1.43 (d, *J* = 7.0 Hz, 3H), 1.27 – 1.24 (m, 2H), 1.22 – 1.20 (m, 8H), 0.86 (t, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 209.4, 166.9, 134.2, 131.6, 128.5, 127.0, 58.3, 39.9, 31.8, 31.4, 29.3, 29.2, 29.1, 27.0, 23.6, 22.6, 22.5, 14.0, 13.8.

FT-IR (film): 2925, 2853, 1714, 1486, 1456, 764, 567 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₃H₃₀ONa: 345.2189, found: 345.2184.

 $[\alpha]^{25_{\rm D}} = -140.9 \ (c \ 1.0, \ CH_2Cl_2); 94\% \ ee \ from \ (R)-L.$



2-([1,1'-Biphenyl]-4-yl)-5-methylhexan-3-one (Fig. 2, compound 5). The title compound was synthesized according to **GP-B** from 3-methylbutanoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:40 EtOAc/Petroleum ether). White solid (mp = 89-90 °C).

(S)-L: 107 mg, 80% yield, 95% ee; (R)-L: 108 mg, 81% yield, 95% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.9 min (minor), 11.3 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.61 – 7.56 (m, 4H), 7.46 – 7.43 (m, 2H), 7.37 – 7.33 (m, 1H), 7.31 – 7.28 (m, 2H), 3.78 (q, *J* = 7.0 Hz, 1H), 2.34 – 2.24 (m, 2H), 2.17 – 2.11 (m, 1H), 1.43 (d, *J* = 7.0 Hz, 3H), 0.88 (d, *J* = 6.7 Hz, 3H), 0.80 (d, *J* = 6.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 210.4, 140.6, 140.0, 139.6, 128.7, 128.3, 127.5, 127.3, 127.0, 52.9, 50.1, 24.4, 22.6, 22.3, 17.4.

FT-IR (film): 2959, 2930, 2871, 1708, 1633, 1470, 1384, 837, 763, 689 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₉H₂₂ONa: 289.1563, found: 289.1559.

 $[\alpha]^{25_{\rm D}}$ = +164.7 (*c* 1.0, CH₂Cl₂); 95% ee from (*S*)-L.



3-([1,1'-Biphenyl]-4-yl)-1-phenylbutan-2-one (Fig. 2, compound 6). The title compound was synthesized according to **GP-B** from 2-phenylacetic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:200 EtOAc/Petroleum ether). White solid (mp = 68-69 °C).

(*S*)-L: 74 mg, 50% yield, 92% ee; (*R*)-L: 81 mg, 54% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 6.7 min (major), 7.5 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.61 – 7.56 (m, 4H), 7.45 (t, *J* = 7.7 Hz, 2H), 7.36 (t, *J* = 7.3 Hz, 1H), 7.30 – 7.22 (m, 5H), 7.09 – 7.08 (m, 2H), 3.91 (q, *J* = 6.9 Hz, 1H), 3.68 (s, 2H), 1.41 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 207.9, 140.6, 140.2, 139.3, 134.3, 129.4, 128.8, 128.5, 128.4, 127.6, 127.3, 127.0, 126.8, 51.7, 48.1, 17.6.

FT-IR (film): 3028, 2922, 1713, 1486, 1453, 1031, 838, 765, 732, 697 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₂H₂₀ONa: 323.1406, found: 323.1404.

 $[\alpha]^{25}$ _D = +192.4 (*c* 1.0, CH₂Cl₂); 92% ee from (*S*)-L.



2-([1,1'-Biphenyl]-4-yl)-8-chlorooctan-3-one (Fig. 2, compound 7). The title compound was synthesized according to **GP-B** from 6-chlorohexanoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:20 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 136 mg, 86% yield, 93% ee; (R)-L: 136 mg, 87% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 9.9 min (minor), 12.5 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.61 – 7.56 (m, 4H), 7.46 – 7.43 (m, 2H), 7.37 – 7.34 (m, 1H), 7.31 – 7.28 (m, 2H), 3.80 (q, *J* = 7.0 Hz, 1H), 3.47 (t, *J* = 6.7 Hz, 2H), 2.49 – 2.37 (m, 2H), 1.72 – 1.66 (m, 2H), 1.59 – 1.52 (m, 2H), 1.44 (d, *J* = 7.0 Hz, 3H), 1.36 – 1.28 (m, 2H).

¹³C NMR (126 MHz, CDCl₃) δ 210.4, 140.5, 140.0, 139.5, 128.7, 128.2, 127.5, 127.3, 126.9, 52.6, 44.7, 40.7, 32.2, 26.2, 23.0, 17.4.

FT-IR (film): 2921, 2851, 1712, 1659, 1633, 1486, 1409, 1180, 1141, 1076, 764, 697 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₀H₂₃ClONa: 337.1330, found: 337.1327.

 $[\alpha]^{25}$ _D = +148.4 (*c* 1.0, CH₂Cl₂); 93% ee from (*S*)-L.



2-([1,1'-Biphenyl]-4-yl)-8-bromooctan-3-one (Fig. 2, compound 8). The title compound was synthesized according to **GP-B** from 6-bromohexanoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:150 EtOAc/Petroleum ether). White solid (mp = 43-45 °C).

(S)-L: 160 mg, 89% yield, 93% ee; (R)-L: 160 mg, 89% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 10.4 min (minor), 13.2 min (major).

¹H NMR (600 MHz, CDCl₃) δ 7.62 – 7.58 (m, 4H), 7.47 – 7.44 (m, 2H), 7.37 – 7.34 (m, 1H), 7.32 – 7.30 (m, 2H), 3.81 (q, *J* = 6.9 Hz, 1H), 3.34 (t, *J* = 6.8 Hz, 2H), 2.49 – 2.38 (m, 2H), 1.80 – 1.75 (m, 2H), 1.60 – 1.52 (m, 2H), 1.45 (d, *J* = 7.0 Hz, 3H), 1.37 – 1.30 (m, 2H).

¹³C NMR (126 MHz, CDCl₃) δ 210.2, 140.4, 139.9, 139.5, 128.7, 128.1, 127.5, 127.2, 126.9, 52.5, 40.5, 33.5, 32.3, 27.4, 22.7, 17.3.

FT-IR (film): 2923, 1711, 1558, 1485, 14566, 839, 763, 729, 696 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₀H₂₃BrONa: 381.0824, found: 381.0819.

 $[\alpha]^{25_{\rm D}}$ = +128.8 (*c* 1.0, CH₂Cl₂); 93% ee from (*S*)-L.



2-([1,1'-Biphenyl]-4-yl)-6,6,6-trifluorohexan-3-one (Fig. 2, compound 9). The title compound was synthesized according to **GP-B** from 4,4,4-trifluorobutanoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:30 EtOAc/Petroleum ether). Yellow oil.

(*S*)-L: 117 mg, 76% yield, 95% ee; (*R*)-L: 114 mg, 74% yield, 97% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.5 min (minor), 9.5 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.61 – 7.58 (m, 4H), 7.48 – 7.44 (m, 2H), 7.39 – 7.35 (m, 1H), 7.31 – 7.29 (m, 2H), 3.83 (q, *J* = 7.0 Hz, 1H), 2.74 – 2.61 (m, 2H), 2.48 – 2.39 (m, 1H), 2.38 – 2.27 (m, 1H), 1.48 (d, *J* = 7.0 Hz, 3H).

¹⁹F NMR (471 MHz, CDCl₃) δ -66.5 (s, 3F).

¹³C NMR (126 MHz, CDCl₃) δ 207.1, 140.4, 138.9, 128.8, 128.1, 127.8, 127.4, 127.0, 126.9 (q, *J*_{C-F} = 276.4 Hz), 52.7, 33.3 (q, *J*_{C-F} = 2.5 Hz), 28.1 (q, *J*_{C-F} = 29.9 Hz), 17.3.

FT-IR (film): 2985, 2919, 1716, 1454, 1299, 1254, 1147, 1093, 837, 761, 726, 691 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₈H₁₇F₃ONa: 329.1124, found: 329.1120.

 $[\alpha]^{25}$ _D = +150.1 (*c* 1.0, CH₂Cl₂); 95% ee from (*S*)-L.



2-([1,1'-Biphenyl]-4-yl)-6-phenoxyhexan-3-one (Fig. 2, compound 10). The title compound was synthesized according to **GP-B** from 4-phenoxybutanoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:60 EtOAc/Petroleum ether). White solid (mp = 75-77 °C).

(*S*)-L: 148 mg, 86% yield, 94% ee; (*R*)-L: 142 mg, 83% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.8 min (major), 9.3 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 7.60 – 7.55 (m, 4H), 7.48 – 7.44 (m, 2H), 7.39 – 7.35 (m, 1H), 7.32 – 7.30 (m, 2H), 7.27 – 7.23 (m, 2H), 6.93 (t, *J* = 7.3 Hz, 1H), 6.83 (d, *J* = 8.0 Hz, 2H), 3.95 – 3.83 (m, 3H), 2.65 (td, *J* = 7.2, 3.1 Hz, 2H), 2.10 – 1.97 (m, 2H), 1.47 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 210.2, 158.7, 140.5, 140.1, 139.5, 129.3, 128.7, 128.2, 127.6, 127.3, 127.0, 120.6, 114.4, 66.5, 52.7, 37.3, 23.5, 17.4.

FT-IR (film): 3028, 2921, 2850, 1713, 1600, 1586, 1497, 1245, 1039, 841, 754, 692 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₄H₂₄O₂Na: 367.1669, found: 367.1665.

 $[\alpha]^{25}$ _D = +110.0 (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



6-([1,1'-Biphenyl]-4-yl)-5-oxoheptanenitrile (Fig. 2, compound 11). The title compound was synthesized according to **GP-B** from 4-cyanobutanoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:10 EtOAc/Petroleum ether). White solid (mp = 83-85 °C).

(S)-L: 122 mg, 88% yield, 94% ee; (R)-L: 125 mg, 90% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 14.6 min (minor), 15.6 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.60 – 7.57 (m, 4H), 7.44 (t, *J* = 7.3 Hz, 2H), 7.37 – 7.33 (m, 1H), 7.28 (d, *J* = 8.2 Hz, 2H), 3.81 (q, *J* = 6.9 Hz, 1H), 2.66 – 2.52 (m, 2H), 2.40 – 2.23 (m, 2H), 1.93 – 1.80 (m, 2H), 1.45 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 209.0, 140.44, 140.36, 139.0, 128.8, 128.2, 127.8, 127.4, 127.0, 119.1, 52.7, 38.7, 19.5, 17.2, 16.3.

FT-IR (film): 2928, 1711, 1450, 1366, 836, 757, 725, 688 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₉H₁₉NONa: 300.1359, found: 300.1355.

 $[\alpha]^{25}$ _D = +157.7 (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



tert-Butyl (5-([1,1'-biphenyl]-4-yl)-4-oxohexyl)carbamate (Fig. 2, compound 12). The title compound was synthesized according to **GP-B** from 4-((*tert*-butoxycarbonyl)amino)butanoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:8 EtOAc/Petroleum ether). White solid (mp = 94-95 °C).

(*S*)-L: 165 mg, 90% yield, 92% ee; (*R*)-L: 170 mg, 92% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 11.6 min (minor), 12.7 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.58 – 7.54 (m, 4H), 7.45 – 7.41 (m, 2H), 7.36 – 7.32 (m, 1H), 7.29 – 7.26 (m, 2H), 4.51 (s, 1H), 3.80 (q, *J* = 7.0 Hz, 1H), 3.07 – 2.97 (m, 2H), 2.46 – 2.42 (m, 2H), 1.76 – 1.63 (m, 2H), 1.43 (d, *J* = 7.0 Hz, 3H), 1.40 (s, 9H).

¹³C NMR (126 MHz, CDCl₃) δ 210.2, 155.9, 140.5, 140.1, 139.4, 128.7, 128.2, 127.6, 127.3, 126.9, 79.0, 52.6, 39.8, 38.0, 28.3, 24.1, 17.3.

FT-IR (film): 2973, 2929, 1710, 1515, 1487, 1449, 1365, 1249, 1168, 764, 697 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₃H₂₉NO₃Na: 390.2040, found: 390.2035.

 $[\alpha]^{25}$ _D = +123.3 (*c* 1.0, CH₂Cl₂); 92% ee from (*S*)-L.



Methyl 5-([1,1'-biphenyl]-4-yl)-4-oxohexanoate (Fig. 2, compound 13). The title compound was synthesized according to **GP-B** from 4-methoxy-4-oxobutanoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:15 EtOAc/Petroleum ether). White solid (mp = 75-76 °C).

(*S*)-L: 118 mg, 80% yield, 95% ee; (*R*)-L: 116 mg, 78% yield, 95% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 25.8 min (major), 28.0 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 7.59 – 7.55 (m, 4H), 7.46 – 7.41 (m, 2H), 7.37 – 7.32 (m, 1H), 7.31 – 7.28 (m, 2H), 3.85 (q, *J* = 7.0 Hz, 1H), 3.65 (s, 3H), 2.78 – 2.56 (m, 3H), 2.51 – 2.44 (m, 1H), 1.46 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 208.9, 173.2, 140.6, 140.2, 139.5, 128.7, 128.3, 127.6, 127.3, 127.0, 52.6, 51.7, 35.7, 28.0, 17.4.

FT-IR (film): 2920, 1736, 1713, 1485, 1434, 1196, 1142, 1132, 1075, 1021, 843, 764, 732, 697 cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₁₉H₂₀O₃Na: 319.1305, found: 319.1300. $[\alpha]^{25}_{25} = \pm 165.5$ (*c* 1.0, CH₂Ch): 95% on from (S)-I

 $[\alpha]^{25_{\text{D}}}$ = +165.5 (*c* 1.0, CH₂Cl₂); 95% ee from (*S*)-L.



3-([1,1'-Biphenyl]-4-yl)-1-methoxybutan-2-one (Fig. 2, compound 14). The title compound was synthesized according to **GP-B** from 2-methoxyacetic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:5 EtOAc/Petroleum ether). White solid (mp = 67-68 °C).

(*S*)-L: 69mg, 54% yield, 94% ee; (*R*)-L: 68 mg, 53% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 11.6 min (minor), 17.1 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.59 – 7.55 (m, 4H), 7.46 – 7.42 (m, 2H), 7.37 – 7.30 (m, 3H), 4.05 (s, 2H), 3.96 (q, *J* = 7.0 Hz, 1H), 3.33 (s, 3H), 1.46 (d, *J* = 7.0 Hz, 3H)

¹³C NMR (101 MHz, CDCl₃) δ 207.9, 140.5, 140.2, 138.9, 128.7, 128.2, 127.6, 127.3, 127.0, 76.2, 59.2, 48.5, 17.2.

FT-IR (film): 2980, 2931, 1725, 1408, 1204, 1125, 1111, 1044, 837, 762, 727, 690 cm⁻¹. HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₇H₁₈O₂Na: 277.1199, found: 277.1196.

 $[\alpha]^{25}$ _D = +188.2 (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



2-([1,1'-Biphenyl]-4-yl)oct-7-en-3-one (Fig. 2, compound 15). The title compound was synthesized according to **GP-B** from hex-5-enoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:60 EtOAc/Petroleum ether). White solid (mp = 43-45 °C).

(S)-L: 79 mg, 57% yield, 93% ee; (R)-L: 79 mg, 57% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 13.0 min (minor), 16.8 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.62 – 7.57 (m, 4H), 7.48 – 7.43 (m, 2H), 7.38 – 7.34 (m, 1H), 7.32 – 7.29 (m, 2H), 5.76 – 5.66 (m, 1H), 4.96 – 4.94 (m, 1H), 4.93 (t, *J* = 1.5 Hz, 1H), 3.82 (q, *J* = 6.9 Hz, 1H), 2.50 – 2.37 (m, 2H), 2.06 – 1.91 (m, 2H), 1.72 – 1.59 (m, 2H), 1.45 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 210.5, 140.6, 140.0, 139.6, 137.9, 128.7, 128.2, 127.5, 127.3, 126.9, 115.0, 52.6, 40.2, 32.9, 22.8, 17.4.

FT-IR (film): 3028, 2973, 2928, 1713, 1639, 1486, 1195, 1180, 910, 764, 697 cm⁻¹. HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₀H₂₂ONa: 301.1563, found: 301.1559.

 $[\alpha]^{25}$ _D = -158.8 (*c* 1.0, CH₂Cl₂); 93% ee from (*R*)-L.



2-([1,1'-Biphenyl]-4-yl)tridec-12-en-3-one (Fig. 2, compound 16). The title compound was synthesized according to **GP-B** from undec-10-enoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:50 EtOAc/Petroleum ether). White solid (mp = 30-31 °C).

(S)-L: 74 mg, 42% yield, 94% ee; (R)-L: 74 mg, 43% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 4.8 min (minor), 5.6 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.60 – 7.55 (m, 4H), 7.46 – 7.42 (m, 2H), 7.37 – 7.33 (m, 1H), 7.30 – 7.28 (m, 2H), 5.84 – 5.74 (m, 1H), 5.00 – 4.90 (m, 2H), 3.80 (q, *J* = 7.0 Hz, 1H), 2.42 – 2.37 (m, 2H), 2.04 – 1.98 (m, 2H), 1.55 – 1.49 (m, 2H), 1.43 (d, *J* = 7.0 Hz, 3H), 1.35 – 1.30 (m, 2H), 1.25 – 1.19 (m, 8H).

¹³C NMR (126 MHz, CDCl₃) δ 210.9, 140.6, 140.0, 139.7, 139.1, 128.7, 128.3, 127.5, 127.3, 127.0, 114.1, 52. 6, 41.1, 33.7, 29.2, 29.0, 28.8, 23.8, 17.5.

FT-IR (film): 2925, 2853, 1713, 1486, 1452, 1007, 907, 841, 763, 696 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₅H₃₂ONa: 371.2345, found: 371.2350.

 $[\alpha]^{25}$ D = +130.0 (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



6-([1,1'-Biphenyl]-4-yl)-1-(thiophen-2-yl)heptane-1,5-dione (Fig. 2, compound 17). The title compound was synthesized according to **GP-B** from 5-oxo-5-(thiophen-2-yl)pentanoic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:15 EtOAc/Petroleum ether). Yellow solid (mp = 102-104 °C).

(*S*)-L: 136mg, 75% yield, 93% ee; (*R*)-L: 135 mg, 74% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (10.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 13.7 min (major), 14.3 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 7.62 (dd, *J* = 3.8, 1.1 Hz, 1H), 7.57 – 7.56 (m, 2H), 7.55 – 7.54 (m, 2H), 7.52 (t, *J* = 2.0 Hz, 1H), 7.45 – 7.41 (m, 2H), 7.36 – 7.32 (m, 1H), 7.29 – 7.27 (m, 2H), 7.05 (dd, *J* = 5.0, 3.8 Hz, 1H), 3.81 (q, *J* = 6.9 Hz, 1H), 2.88 – 2.73 (m, 2H), 2.55 (td, *J* = 7.1, 1.6 Hz, 2H), 2.01 – 1.93 (m, 2H), 1.44 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 210.2, 192.6, 144.1, 140.5, 140.0, 139.3, 133.4, 131.8, 128.7, 128.2, 128.0, 127.5, 127.3, 126.9, 52.6, 39.8, 38.0, 18.6, 17.3.

FT-IR (film): 2922, 1707, 1654, 1484, 1412, 1384, 1196, 1180, 1142, 1022, 763, 695 cm⁻¹. HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₃H₂₂O₂SNa: 385.1233, found: 385.1228.

 $[\alpha]^{25}$ _D = +132.2 (*c* 1.0, CH₂Cl₂); 93% ee from (*S*)-L.



2-([1,1'-Biphenyl]-4-yl)-1-(naphthalen-2-yl)butan-1-one (Fig. 2, compound 18). The title compound was synthesized according to **GP-D** from 2-naphthoic acid and 4-propylbiphenyl. The product was purified by preparative thin-layer chromatography on silica gel (1:30 EtOAc/Petroleum ether). White solid (mp = 112-115 °C).

(*S*, *R*)-**L3**: 66 mg, 37% yield, 69% ee; (*R*, *S*)-**L3**: 54 mg, 31% yield, 71% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (1.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (S, R)-L: 12.9 min (major), 14.3 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 8.56 (s, 1H), 8.08 (dd, *J* = 8.6, 1.8 Hz, 1H), 7.95 (d, *J* = 8.2 Hz, 1H), 7.87 – 7.82 (m, 2H), 7.59 – 7.51 (m, 6H), 7.48 – 7.45 (m, 2H), 7.43 – 7.39 (m, 2H), 7.34 – 7.30 (m, 1H), 4.69 (t, *J* = 7.3 Hz, 1H), 2.37 – 2.28 (m, 1H), 2.04 – 1.94 (m, 1H), 1.01 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 120.0, 140.6, 139.8, 138.7, 135.4, 134.3, 132.4, 130.3, 129.6, 128.7, 128.6, 128.4, 128.3, 127.65, 127.55, 127.2, 126.9, 126.6, 124.4, 55.1, 27.2, 12.4.

FT-IR (film): 2922, 2851, 1670, 1483, 1274, 756, 969 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₆H₂₂ONa: 373.1563, found: 373.1559.

 $[\alpha]^{25_{\rm D}}$ = +113.3 (*c* 1.0, CH₂Cl₂); 71% ee from (*R*, *S*)-L.



2-([1,1'-Biphenyl]-4-yl)-1-(4-(trifluoromethyl)phenyl)butan-1-one (Fig. 2, compound 19). The title compound was synthesized according to **GP-D** from 4-(trifluoromethyl)benzoic acid and 4-propylbiphenyl. The product was purified by preparative thin-layer chromatography on silica gel (1:30 EtOAc/Petroleum ether). Colorless oil.

(*S*, *R*)-L3: 78 mg, 42% yield, 76% ee; (*R*, *S*)-L3: 88 mg, 46% yield, 77% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (1.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 12.4 min (major), 19.0 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 8.08 (d, *J* = 8.2 Hz, 2H), 7.67 (d, *J* = 8.3 Hz, 2H), 7.56 – 7.53 (m, 4H), 7.42 (t, *J* = 7.7 Hz, 2H), 7.36 – 7.31 (m, 3H), 4.47 (t, *J* = 7.2 Hz, 1H), 2.28 – 2.23 (m, 1H), 1.95 – 1.89 (m, 1H), 0.96 (t, *J* = 7.4 Hz, 3H).

¹⁹F NMR (471 MHz, CDCl₃) δ -63.1 (s, 3F).

¹³C NMR (101 MHz, CDCl₃) δ 199.0, 140.4, 140.2, 139.7, 137.9, 134.0 (q, *J*_{C-F} = 32.8 Hz), 128.9, 128.7, 128.6, 127.7, 127.3, 127.0, 125.6 (q, *J*_{C-F} = 3.8 Hz), 123.5 (q, *J*_{C-F} = 273.7 Hz), 55.6, 26.9, 12.2.

FT-IR (film): 2964, 2925, 1687, 1485, 1408, 1323, 1129, 1066, 759, 696 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₃H₁₉F₃ONa: 391.1280, found: 391.1277.

 $[\alpha]^{25}$ D = -72.4 (*c* 1.0, CH₂Cl₂); 77% ee from (*R*, *S*)-L.



1,4-Diphenylpentan-3-one (Fig. 2, compound 20). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and ethylbenzene. The product was purified by column chromatography on silica gel (1:90 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 105 mg, 88% yield, 93% ee; (*R*)-L: 100 mg, 84% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 5.7 min (major), 6.2 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.33 – 7.29 (m, 2H), 7.27 – 7.21 (m, 3H), 7.19 – 7.15 (m, 3H), 7.09 – 7.06 (m, 2H), 3.72 (q, *J* = 7.0 Hz, 1H), 2.90 – 2.84 (m, 1H), 2.82 – 2.76 (m, 1H), 2.74 – 2.62 (m, 2H), 1.40 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 209.8, 141.0, 140.4, 128.9, 128.3, 128.2, 127.8, 127.1, 125.9, 53.2, 42.5, 29.9, 17.3.

FT-IR (film): 3027, 2974, 1713, 1601, 1494, 1453, 1373, 1073, 1029, 751, 699, cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₁₇H₁₈ONa: 261.1250, found: 261.1252. [α]²⁵_D = -142.5 (*c* 1.0, CH₂Cl₂); 93% ee from (*R*)-L.



4-(4-Methoxyphenyl)-1-phenylpentan-3-one (Fig. 2, compound 21). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 4-(4-methoxyphenyl)-1-phenylpentan-3-one. The product was purified by column chromatography on silica gel (1:5 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 105 mg, 78% yield, 95% ee; (*R*)-L: 107 mg, 80% yield, 95% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 13.8 min (minor), 15.4 min (major).

¹H NMR (500 MHz, CD₂Cl₂) δ 7.25 – 7.21 (m, 2H), 7.18 – 7.14 (m, 1H), 7.12 – 7.07 (m, 4H), 6.87 – 6.84 (m, 2H), 3.79 (s, 3H), 3.69 (q, *J* = 6.9 Hz, 1H), 2.87 – 2.63 (m, 4H), 1.35 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CD₂Cl₂) δ 210.2, 159.2, 141.7, 133.0, 129.3, 128.7, 128.6, 126.3, 114.6, 55.6, 52.5, 42.7, 30.2, 17.6.

FT-IR (film): 3027, 2931, 1712, 1609, 1510, 1454, 1247, 1178, 1032, 832, 783, 699 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₈H₂₀O₂Na: 291.1356, found: 291.1352.

 $[\alpha]^{25}$ _D = +125.9 (*c* 1.0, CH₂Cl₂); 95% ee from (*S*)-L.



4-(3-Oxo-5-phenylpentan-2-yl)phenyl acetate (Fig. 2, compound 22). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 4-ethylphenyl acetate. The product was purified by column chromatography on silica gel (1:5 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 115 mg, 78% yield, 97% ee; (R)-L: 119 mg, 80% yield, 97% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 23.3 min (minor), 24.1 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.25 – 7.21 (m, 2H), 7.18 – 7.14 (m, 3H), 7.09 – 7.07 (m, 2H), 7.04 – 7.01 (m, 2H), 3.71 (q, *J* = 7.0 Hz, 1H), 2.89 – 2.75 (m, 2H), 2.73 – 2.63 (m, 2H), 2.29 (s, 3H), 1.37 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 209.5, 169.3, 149.7, 140.9, 137.8, 128.8, 128.4, 128.2, 126.0, 121.9, 52.4, 42.6, 29.9, 21.1, 17.4.

FT-IR (film): 2929, 1757, 1711, 1516, 1452, 1368, 1197, 1076, 1016, 909, 744, 698 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₉H₂₀O₃Na: 319.1305, found: 319.1302.

 $[\alpha]^{25}$ D = +98.3 (*c* 1.0, CH₂Cl₂); 97% ee from (*S*)-L.



N-(4-(3-Oxo-5-phenylpentan-2-yl)phenyl)acetamide (Fig. 2, compound 23). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and *N*-(4-ethylphenyl)acetamide. The product was purified by column chromatography on silica gel (2:3 EtOAc/Petroleum ether). Yellow oil.

(*S*)-L: 96 mg, 65% yield, 95% ee; (*R*)-L: 104 mg, 70% yield, 95% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (10.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 27.4 min (minor), 30.1 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.45 – 7.40 (m, 3H), 7.24 – 7.20 (m, 2H), 7.17 – 7.15 (m, 1H), 7.12 – 7.05 (m, 4H), 3.67 (q, *J* = 6.9 Hz, 1H), 2.88 – 2.71 (m, 2H), 2.69 – 2.63 (m, 2H), 2.16 (s, 3H), 1.34 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 209.9, 168.3, 140.9, 136.9, 136.2, 128.4, 128.2, 126.0, 120.3, 52.5, 42.5, 29.9, 24.5, 17.3.

FT-IR (film): 3027, 2972, 1709, 1666, 1602, 1534, 1411, 1316, 1267, 837, 747, 700, cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+ Na]⁺ calcd for C₁₉H₂₁NO₂Na: 318.1465, found: 318.1462.

 $[\alpha]^{25}$ D = +86.9 (*c* 1.0, CH₂Cl₂); 95% ee from (*S*)-L.



4-(4-Fluorophenyl)-1-phenylpentan-3-one (Fig. 2, compound 24). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 1-ethyl-4-fluorobenzene. The product was purified by column chromatography on silica gel (1:30 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 97 mg, 75% yield, 93% ee; (R)-L: 98 mg, 77% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 7.9 min (minor), 9.4 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.25 – 7.22 (m, 2H), 7.19 – 7.16 (m, 1H), 7.13 – 7.11 (m, 2H), 7.09 – 7.07 (m, 2H), 7.00 – 6.97 (m, 2H), 3.71 (q, *J* = 7.0 Hz, 1H), 2.90 – 2.77 (m, 2H), 2.74 – 2.64 (m, 2H), 1.37 (d, *J* = 7.0 Hz, 3H).

¹⁹F NMR (471 MHz, CDCl₃) δ –115.5 (s, 1F).

¹³C NMR (126 MHz, CDCl₃) δ 209.5, 161.9 (d, *J*_{C-F} = 246.0 Hz), 140.9, 136.0 (d, *J*_{C-F} = 3.3 Hz), 129.3 (d, *J*_{C-F} = 8.1 Hz), 128.4, 128.2, 126.0, 115.7 (d, *J*_{C-F} = 21.4 Hz), 52.3, 42.5, 29.9, 17.4.

FT-IR (film): 3027, 2931, 1714, 1602, 1508, 1224, 1159, 1076, 836, 749, 699 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₇H₁₇FONa: 279.1156, found: 279.1152.

 $[\alpha]^{25_{\rm D}}$ = +110.9 (*c* 1.0, CH₂Cl₂); 93% ee from (*S*)-L.



4-(4-Acetylphenyl)-1-phenylpentan-3-one (Fig. 2, compound 25). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 1-(4-ethylphenyl)ethan-1-one. The product was purified by column chromatography on silica gel (1:10 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 95 mg, 68% yield, 92% ee; (*R*)-L: 94 mg, 67% yield, 90% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (10.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.6 min (major), 10.3 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 7.89 – 7.86 (m, 2H), 7.26 – 7.18 (m, 4H), 7.17 – 7.12 (m, 1H), 7.07 – 7.03 (m, 2H), 3.78 (q, *J* = 7.0 Hz, 1H), 2.89 – 2.74 (m, 2H), 2.70 – 2.66 (m, 2H), 2.58 (s, 3H), 1.39 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 208.8, 197.5, 145.6, 140.7, 136.0, 128.9, 128.3, 128.2, 128.0, 126.0, 53.0, 42.8, 29.8, 26.5, 17.2.

FT-IR (film): 3027, 2931, 1715, 1682, 1605, 1412, 1358, 1267, 1057, 837, 700, 598 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₉H₂₀O₂Na: 303.1356, found: 303.1352.

 $[\alpha]^{25_{\rm D}}$ = +91.8 (*c* 1.0, CH₂Cl₂); 92% ee from (*S*)-L.



Methyl 4-(3-oxo-5-phenylpentan-2-yl)benzoate (Fig. 2, compound 26). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and methyl 4-ethylbenzoate. The product was purified by column chromatography on silica gel (1:10 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 103 mg, 69% yield, 92% ee; (R)-L: 101 mg, 68% yield, 90% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (10.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.9 min (minor), 9.5 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.97 – 7.95 (m, 2H), 7.23 – 7.19 (m, 4H), 7.17 – 7.14 (m, 1H), 7.06 – 7.04 (m, 2H), 3.91 (s, 3H), 3.76 (q, *J* = 7.0 Hz, 1H), 2.88 – 2.75 (m, 2H), 2.68 – 2.65 (m, 2H), 1.39 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 208.9, 166.7, 145.4, 140.7, 130.2, 129.1, 128.4, 128.2, 127.9, 126.0, 53.1, 52.1, 42.8, 29.8, 17.2.

FT-IR (film): 3027, 2931, 1717, 1608, 1435, 1279, 1111, 1018, 858, 768, 747, 700 cm⁻¹. HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₉H₂₀O₃Na: 319.1305, found: 319.1301. [α]²⁵_D = +88.9 (*c* 1.0, CH₂Cl₂); 92% ee from (*S*)-L.



4-(3-Oxo-5-phenylpentan-2-yl)benzonitrile (Fig. 2, compound 27). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 4-ethylbenzonitrile. The product was purified by column chromatography on silica gel (1:18 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 81 mg, 61% yield, 88% ee; (*R*)-L: 81 mg, 62% yield, 88% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC-3 column (10.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 16.6 min (major), 18.0 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 7.57 – 7.55 (m, 2H), 7.24 – 7.15 (m, 5H), 7.06 – 7.04 (m, 2H), 3.77 (q, *J* = 7.0 Hz, 1H), 2.86 – 2.81 (m, 2H), 2.71 – 2.66 (m, 2H), 1.38 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 208.2, 145.4, 140.5, 132.5, 128.6, 128.4, 128.2, 126.1, 118.5, 111.0, 53.0, 42.9, 29.7, 17.2.

FT-IR (film): 2923, 1716, 1604, 1497, 1452, 1058, 840, 746, 694 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₈H₁₇NONa: 286.1202, found: 286.1202.

 $[\alpha]^{25}$ D = +78.8 (*c* 1.0, CH₂Cl₂); 88% ee from (*S*)-L.



1-Phenyl-4-(*p***-tolyl)pentan-3-one (Fig. 2, compound 28).** The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 1-ethyl-4-methylbenzene. The product was purified by column chromatography on silica gel (1:60 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 84 mg, 67% yield, 93% ee; (*R*)-L: 78 mg, 62% yield, 95% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 7.7 min (minor), 8.2 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.28 – 7.25 (m, 2H), 7.21 – 7.18 (m, 1H), 7.16 – 7.15 (m, 2H), 7.12 – 7.09 (m, 4H), 3.71 (q, *J* = 6.9 Hz, 1H), 2.93 – 2.87 (m, 1H), 2.85 – 2.77 (m, 1H), 2.76 – 2.65 (m, 2H), 2.37 (s, 3H), 1.41 (d, *J* = 7.0, Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 209.9, 141.0, 137.4, 136.7, 129.5, 128.3, 128.2, 127.7, 125.9, 52.7, 42.4, 29.9, 21.0, 17.3.

FT-IR (film): 2974, 2928, 1712, 1513, 1453, 1372, 1060, 819, 747, 698 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₈H₂₀ONa: 275.1406, found: 275.1404.

 $[\alpha]^{25_{\rm D}}$ = +125.1 (*c* 1.0, CH₂Cl₂); 93% ee from (*S*)-L.



4-(4-Ethylphenyl)-1-phenylpentan-3-one (Fig. 2, compound 29). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 1,4-diethylbenzene. The product was purified by column chromatography on silica gel (1:20 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 80 mg, 60% yield, 95% ee; (*R*)-L: 77 mg, 58% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 6.4 min (minor), 6.7 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.22 – 7.17 (m, 2H), 7.15 – 7.11 (m, 3H), 7.07 – 7.04 (m, 4H), 3.66 (q, *J* = 6.9 Hz, 1H), 2.88 – 2.70 (m, 2H), 2.69 – 2.58 (m, 4H), 1.35 (d, *J* = 7.0 Hz, 3H), 1.22 (t, *J* = 7.6 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 210.0, 143.0, 141.1, 137.6, 128.33, 128.29, 128.2, 127.7, 125.9, 52.7, 42.4, 29.9, 28.4, 17.3, 15.4.

FT-IR (film): 2966, 2930, 1713, 1511, 1453, 1372, 1180, 1130, 1061, 833, 748, 698 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₉H₂₂ONa: 289.1563, found: 289.1560.

 $[\alpha]^{25}$ _D = +117.9 (*c* 1.0, CH₂Cl₂); 95% ee from (*S*)-L.



4-(3,5-Diethylphenyl)-1-phenylpentan-3-one (Fig. 2, compound 30). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 1,3,5-triethylbenzene. The product was purified by column chromatography on silica gel (1:40 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 95 mg, 65% yield, 93% ee; (*R*)-L: 100 mg, 68% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (1.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 4.4 min (major), 4.8 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 7.28 – 7.23 (m, 2H), 7.20 – 7.16 (m, 1H), 7.12 – 7.09 (m, 2H), 6.97 (s, 1H), 6.85 (s, 2H), 3.70 (q, *J* = 6.9 Hz, 1H), 2.94 – 2.68 (m, 4H), 2.63 (q, *J* = 7.6 Hz, 4H), 1.41 (d, *J* = 6.9 Hz, 3H), 1.26 (t, *J* = 7.6 Hz, 6H).

¹³C NMR (101 MHz, CDCl₃) δ 210.1, 144.8, 141.1, 140.4, 128.3, 128.2, 126.3, 125.9, 124.7, 53.1, 42.4, 30.0, 28.7, 17.3, 15.5.

FT-IR (film): 2965, 2931, 1713, 1600, 1454, 1372, 1076, 868, 711, 699 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₁H₂₆ONa: 317.1876, found: 317.1872.

 $[\alpha]^{25}$ _D = +119.6 (*c* 1.0, CH₂Cl₂); 93% ee from (*S*)-L.



4-(3-Fluorophenyl)-1-phenylpentan-3-one (Fig. 2, compound 31). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 1-ethyl-3-fluorobenzene. The product was purified by column chromatography on silica gel (1:30 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 79 mg, 62% yield, 93% ee; (*R*)-L: 79 mg, 62% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 7.3 min (minor), 7.4 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.33 – 7.25 (m, 3H), 7.23 – 7.19 (m, 1H), 7.14 – 7.11 (m, 2H), 7.01 – 6.96 (m, 2H), 6.94 – 6.91 (m, 1H), 3.75 (q, *J* = 7.0 Hz, 1H), 2.95 – 2.82 (m, 2H), 2.80 – 2.68 (m, 2H), 1.42 (d, *J* = 7.0 Hz, 3H).

¹⁹F NMR (471 MHz, CDCl₃) δ -112.2 (s, 1F).

¹³C NMR (101 MHz, CDCl₃) δ 209.0, 163.0 (d, *J*_{C-F} = 247.8 Hz), 142.7 (d, *J*_{C-F} = 7.4 Hz), 140.8, 130.3 (d, *J*_{C-F} = 8.4 Hz), 128.3, 128.2, 126.0, 123.5 (d, *J*_{C-F} = 3.1 Hz), 114.7 (d, *J*_{C-F} = 21.7 Hz), 114.0 (d, *J*_{C-F} = 21.1 Hz), 52.7, 42.5, 29.8, 17.2.

FT-IR (film): 3027, 2931, 1713, 1589, 1489, 1449, 1057, 907, 783, 697 cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₁₇H₁₇FONaS: 279.1156, found: 279.1153. [α]²⁵_D = +104.1 (*c* 1.0, CH₂Cl₂); 93% ee from (*S*)-L.



4-(3-Bromophenyl)-1-phenylpentan-3-one (Fig. 2, compound 32). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 1-bromo-3-ethylbenzene. The product was purified by column chromatography on silica gel (1:20 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 108 mg, 68% yield, 93% ee; (*R*)-L: 100 mg, 63% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 7.7 min (minor), 8.7 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.34 (m, 1H), 7.31 (t, *J* = 1.7 Hz, 1H), 7.23 – 7.19 (m, 2H), 7.16 – 7.11 (m, 2H), 7.07 -7.04 (m, 3H), 3.64 (q, *J* = 6.9 Hz, 1H), 2.86 – 2.75 (m, 2H), 2.68 – 2.64 (m, 2H), 1.34 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 209.0, 142.6, 140.8, 130.9, 130.4, 130.3, 128.4, 128.2, 126.4, 126.1, 122.9, 52.7, 42.7, 29.8, 17.3.

FT-IR (film): 3027, 2929, 1713, 1590, 1567, 1495, 1453, 1425, 1373, 1074, 749, 696 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₇H₁₇BrONa: 339.0355, found: 339.0354.

 $[\alpha]^{25_{\rm D}}$ = +80.0 (*c* 1.0, CH₂Cl₂); 93% ee from (*S*)-L.



4-(2-Bromophenyl)-1-phenylpentan-3-one (Fig. 2, compound 33). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 1-bromo-2-ethylbenzene. The product was purified by column chromatography on silica gel (1:20 EtOAc/Petroleum ether). Light yellow oil.

(S)-L: 58 mg, 36% yield, 91% ee; (R)-L: 59 mg, 37% yield, 90% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 7.4 min (minor), 8.4 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.59 (dd, *J* = 8.0, 1.1 Hz, 1H), 7.25 – 7.21 (m, 3H), 7.19 – 7.15 (m, 1H), 7.13 – 7.08 (m, 3H), 7.05 (dd, *J* = 7.7, 1.6 Hz, 1H), 4.27 (q, *J* = 6.9 Hz, 1H), 2.93 – 2.80 (m, 2H), 2.71 – 2.67 (m, 2H), 1.36 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 209.1, 140.9, 140.0, 133.2, 128.60, 128.58, 128.4, 128.3, 128.0, 126.0, 124.8, 51.6, 43.0, 29.9, 16.5.

FT-IR (film): 3026, 2930, 1716, 1453, 1438, 1373, 1180, 1132, 1022, 751, 699 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₇H₁₇BrONa: 339.0355, found: 339.0357.

 $[\alpha]^{25_{\rm D}}$ = +120.3 (*c* 1.0, CH₂Cl₂); 91% ee from (*S*)-L.



1-Phenyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pentan-3-one (Fig. 2, compound 34). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 2-(4-ethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. The product was purified by column chromatography on silica gel (1:30 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 130 mg, 71% yield, 94% ee; (*R*)-L:125 mg, 68% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 5.2 min (major), 7.7 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, *J* = 8.0 Hz, 2H), 7.22 – 7.13 (m, 5H), 7.06 – 7.01 (m, 2H), 3.69 (q, *J* = 6.9 Hz, 1H), 2.88 – 2.69 (m, 2H), 2.66 – 2.61 (m, 2H), 1.36 (d, *J* = 6.9 Hz, 3H), 1.33 (s, 12H).

¹³C NMR (101 MHz, CDCl₃) δ 209.3, 143.5, 140.8, 135.3, 134.8, 128.3, 128.1, 127.2, 125.9, 83.7, 53.3, 42.5, 29.8, 24.7, 17.1.

FT-IR (film): 2977, 2930, 1715, 1609, 1361, 1143, 1091, 859, 748, 659 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₃H₂₉BO₃Na: 387.2102, found: 387.2099.

 $[\alpha]^{25}D = +69.3$ (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



4-(4-(1*H***-Pyrazol-1-yl)phenyl)-1-phenylpentan-3-one (Fig. 2, compound 35).** The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 1-(4-ethylphenyl)-1*H*-pyrazole. The product was purified by column chromatography on silica gel (1:5 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 118 mg, 78% yield, 95% ee; (R)-L: 121 mg, 80% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK ID column (10.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 17.8 min (major), 21.5 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 7.89 (d, *J* = 2.3 Hz, 1H), 7.71 (d, *J* = 1.4 Hz, 1H), 7.63 – 7.60 (m, 2H), 7.25 – 7.19 (m, 4H), 7.16 – 7.11 (m, 1H), 7.07 – 7.05 (m, 2H), 6.45 (t, *J* = 2.0 Hz, 1H), 3.73 (q, *J* = 6.9 Hz, 1H), 2.89 – 2.63 (m, 4H), 1.39 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 209.4, 141.0, 140.8, 139.1, 138.5, 128.8, 128.3, 128.2, 126.6, 126.0, 119.5, 107.6, 52.5, 42.6, 29.8, 17.2.

FT-IR (film): 2971, 2929, 1712, 1524, 1394, 1333, 1046, 936, 840, 749, 699 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₀H₂₀N₂ONa: 327.1468, found: 327.1465.

 $[\alpha]^{25}$ D = +90.7 (*c* 1.0, CH₂Cl₂); 95% ee from (*S*)-L.



1-Phenyl-4-(thiophen-3-yl)pentan-3-one (Fig. 2, compound 36). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 1-phenyl-4-(thiophen-3-yl)pentan-3-one. The product was purified by column chromatography on silica gel (1:60 EtOAc/Petroleum ether). Yellow oil.

(*S*)-L: 90 mg, 74% yield, 86% ee; (*R*)-L: 88 mg, 72% yield, 86% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 5.3 min (major), 5.5 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.29 – 7.25 (m, 3H), 7.21 – 7.18 (m, 1H), 7.13 – 7.11 (m, 2H), 7.05 – 7.04 (m, 1H), 6.93 (dd, *J* = 5.0, 1.3 Hz, 1H), 3.87 (q, *J* = 7.0 Hz, 1H), 2.92 – 2.80 (m, 2H), 2.79 – 2.66 (m, 2H), 1.41 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 209.4, 140.9, 140.5, 128.3, 128.2, 126.9, 126.1, 125.9, 121.4, 48.3, 42.0, 29.8, 16.9.

FT-IR (film): 3026, 2931, 1713, 1453, 1371, 1113, 1058, 865, 772, 699 cm⁻¹.

HRMS (ESI-MS) m/z [M+Na]+ calcd for C15H16OSNa: 267.0814, found: 267.0814.

 $[\alpha]^{25}$ _D = +81.4 (c 1.0, CH₂Cl₂); 86% ee from (*S*)-L.



4-(Naphthalen-2-yl)-1-phenylpentan-3-one (Fig. 2, compound 37). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 2-ethylnaphthalene. The product was purified by column chromatography on silica gel (1:60 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 103 mg, 71% yield, 94% ee; (R)-L: 105 mg, 73% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 5.9 min (major), 6.8 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.84 – 7.78 (m, 3H), 7.63 (s, 1H), 7.51 – 7.46 (m, 2H), 7.29 (dd, *J* = 8.4, 1.7 Hz, 1H), 7.21 – 7.18 (m, 2H), 7.15 – 7.12 (m, 1H), 7.06 – 7.04 (m, 2H), 3.89 (q, *J* = 7.0 Hz, 1H), 2.91 – 2.85 (m, 1H), 2.83 – 2.77 (m, 1H), 2.75 – 2.68 (m, 2H), 1.48 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 209.8, 140.9, 137.9, 133.6, 132.5, 128.7, 128.3, 128.2, 127.7, 127.6, 126.6, 126.2, 126.0, 125.9, 125.8, 53.3, 42.6, 29.9, 17.3.

FT-IR (film): 3058, 2971, 1712, 1452, 1375, 1180, 1076, 1054, 857, 820, 699 cm⁻¹. HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₁H₂₀ONa: 311.1406, found: 311.1403.

 $[\alpha]^{25}$ _D = +126.4 (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



1,4-Diphenylheptan-3-one (Fig. 2, compound 38). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and butylbenzene. The product was purified by column chromatography on silica gel (1:40 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 89 mg, 67% yield, 94% ee; (R)-L: 85 mg, 64% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.0 min (minor), 8.4 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.30 – 7.25 (m, 2H), 7.24 – 7.11 (m, 6H), 7.06 – 7.04 (m, 2H), 3.57 (t, *J* = 7.4Hz, 1H), 2.88 – 2.71 (m, 2H), 2.69 – 2.59 (m, 2H), 2.03 – 1.94 (m, 1H), 1.71 – 1.61 (m, 1H), 1.22 – 1.12 (m, 2H), 0.86 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 209.5, 141.0, 138.9, 128.8, 128.3, 128.21, 128.19, 127.1, 125.9, 58.9, 43.3, 34.0, 29.8, 20.6, 13.9.

FT-IR (film): 2957, 2931, 1713, 1494, 1453, 1180, 1131, 1075, 750, 699 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₉H₂₂ONa: 289.1568, found: 289.1571.

 $[\alpha]^{25}$ D = +128.2 (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



6-Methyl-1,4-diphenylheptan-3-one (Fig. 2, compound 39). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and isopentylbenzene. The product was purified by column chromatography on silica gel (1:40 EtOAc/Petroleum ether). Light yellow oil.

(S)-L: 75 mg, 54% yield, 93% ee; (R)-L: 70 mg, 50% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (1.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 5.6 min (major), 6.2 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 7.30 – 7.26 (m, 2H), 7.24 – 7.11 (m, 6H), 7.06 – 7.03 (m, 2H), 3.67 (dd, *J* = 8.0, 7.0 Hz, 1H), 2.87 – 2.64 (m, 4H), 1.89 – 1.82 (m, 1H), 1.66 – 1.59 (m, 1H), 1.39 – 1.29 (m, 1H), 0.85 (d, *J* = 3.0 Hz, 3H), 0.83 (d, *J* = 3.0 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 209.5, 141.0, 139.0, 128.8, 128.33, 128.26, 128.2, 127.1, 125.9, 57.0, 43.2, 40.8, 29.9, 25.5, 23.0, 22.1.

FT-IR (film): 2955, 2930, 1713, 1494, 1466, 1453, 1367, 1069, 749, 699 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₀H₂₄ONa: 303.1719, found: 303.1716.

 $[\alpha]^{25_{\rm D}}$ = +125.7 (*c* 1.0, CH₂Cl₂); 93% ee from (*S*)-L.



Ethyl 4-oxo-3,6-diphenylhexanoate (Fig. 2, compound 40). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and ethyl 3-phenylpropanoate. The product was purified by column chromatography on silica gel (1:5 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 82 mg, 53% yield, 95% ee; (R)-L: 79 mg, 51% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 11.4 min (major), 12.9 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.32 – 7.25 (m, 3H), 7.23 – 7.19 (m, 2H), 7.17 – 7.13 (m, 3H), 7.07 – 7.05 (m, 2H), 4.18 (dd, *J* = 9.9, 5.0 Hz, 1H), 4.14 – 4.08 (m, 2H), 3.23 (dd, *J* = 16.9, 9.9 Hz, 1H), 2.90 – 2.86 (m, 1H), 2.82 – 2.71 (m, 3H), 2.55 (dd, *J* = 17.0, 5.0 Hz, 1H), 1.22 (t, *J* = 7.2 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 207.8, 172.0, 140.8, 137.2, 129.1, 128.3, 128.19, 128.17, 127.6, 125.9, 60.6, 54.2, 43.0, 37.1, 29.6, 14.1.

FT-IR (film): 3027, 2927, 1716, 1495, 1453, 1372, 1241, 1075, 1027, 753, 699 cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₂₀H₂₂O₃Na: 333.1461, found: 333.1457. [α]²⁵_D = +178.8 (*c* 1.0, CH₂Cl₂); 95% ee from (*S*)-L.



4-Oxo-3,6-diphenylhexyl acetate (Fig. 2, compound 41). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 3-phenylpropyl acetate. The product was purified by column chromatography on silica gel (1:10 EtOAc/Petroleum ether). Yellow oil.

(S)-L: 101 mg, 65% yield, 95% ee; (R)-L: 102 mg, 66% yield, 95% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 7.8 min (major), 8.3 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.32 – 7.28 (m, 2H), 7.27 – 7.26 (m, 1H), 7.24 – 7.20 (m, 2H), 7.17 – 7.12 (m, 3H), 7.06 – 7.04 (m, 2H), 4.03 – 3.98 (m, 1H), 3.90 – 3.85 (m, 1H), 3.71 (t, *J* = 7.2 Hz, 1H), 2.89 – 2.83 (m, 1H), 2.79 – 2.73 (m, 1H), 2.70 – 2.66 (m, 2H), 2.42 – 2.34 (m, 1H), 2.02 – 1.95 (m, 4H).

¹³C NMR (126 MHz, CDCl₃) δ 208.4, 170.9, 140.8, 137.8, 129.1, 128.4, 128.25, 128.19, 127.5, 126.0, 62.3, 55.6, 43.1, 30.8, 29.8, 20.8.

FT-IR (film): 3027, 2926, 1712, 1493, 1453, 1364, 1236, 1038, 751, 699 cm⁻¹. HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₀H₂₂O₃Na: 333.1461, found: 333.1457. [α]²⁵D = +161.5 (*c* 1.0, CH₂Cl₂); 95% ee from (*S*)-L.



7-((*tert***-Butyldimethylsilyl)oxy)-1,4-diphenylheptan-3-one (Fig. 2, compound 42).** The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and *tert*-butyldimethyl(4-phenylbutoxy)silane. The product was purified by column chromatography on silica gel (1:40 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 131 mg, 66% yield, 95% ee; (*R*)-L: 136 mg, 69% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALAPK AD-3 column (1.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 4.6 min (major), 4.9 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.33 – 7.29 (m, 2H), 7.27 – 7.24 (m, 1H), 7.23 – 7.21 (m, 2H), 7.19 – 7.16 (m, 3H), 7.08 – 7.06 (m, 2H), 3.65 – 3.57 (m, 3H), 2.90 – 2.84 (m, 1H), 2.80 – 2.65 (m, 3H), 2.11 – 2.05 (m, 1H), 1.81 – 1.74 (m, 1H), 1.46 – 1.34 (m, 2H), 0.90 (s, 9H), 0.04 (d, *J* = 2.6 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 209.3, 140.9, 138.7, 128.8, 128.3, 128.2, 128.2, 127.1, 125.9, 62.9, 58.9, 43.2, 30.5, 29.8, 28.3, 25.9, 18.3, -5.3.

FT-IR (film): 2928, 2856, 1714, 1495, 1453, 1360, 1099, 835, 775, 699 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₅H₃₆O₂SiNa: 419.2377, found: 419.2373.

 $[\alpha]^{25}$ D = +90.3 (*c* 1.0, CH₂Cl₂); 95% ee from (*S*)-L.



6-Bromo-1,4-diphenylhexan-3-one (Fig. 2, compound 43). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and (3-bromopropyl)benzene. The product was purified by column chromatography on silica gel (1:40 EtOAc/Petroleum ether). Yellow oil.

(S)-L: 83 mg, 50% yield, 80% ee; (R)-L: 82 mg, 50% yield, 83% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.4 min (minor), 9.7 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.34 – 7.27 (m, 3H), 7.24 – 7.21 (m, 2H), 7.18 – 7.14 (m, 3H), 7.08 – 7.06 (m, 2H), 3.94 (dd, *J* = 8.1, 6.4 Hz, 1H), 3.39 – 3.35 (m, 1H), 3.18 – 3.13 (m, 1H), 2.91 – 2.85 (m, 1H), 2.81 – 2.75 (m, 1H), 2.72 – 2.69 (m, 2H), 2.56 – 2.49 (m, 1H), 2.25 – 2.18 (m, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 208.4, 140.7, 137.2, 129.2, 128.4, 128.4, 128.2, 127.7, 126.0, 56.6, 43.2, 34.4, 31.9, 29.8.

FT-IR (film): 2924, 2854, 1711, 1601, 1493, 1453, 1359, 1253, 1180, 1075, 1029, 753, 698 cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₁₈H₁₉BrONa: 353.0511, found: 353.0509. [α]²⁵_D = +152.4 (*c* 1.0, CH₂Cl₂); 80% ee from (*S*)-L.



6-Chloro-1,4-diphenylhexan-3-one (Fig. 2, compound 44). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and (3-chloropropyl)benzene. The product was purified by column chromatography on silica gel (1:40 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 85 mg, 59% yield, 94% ee; (*R*)-L: 88 mg, 61% yield, 95% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.7 min (minor), 9.4 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.26 (m, 3H), 7.25 – 7.21 (m, 2H), 7.18 – 7.14 (m, 3H), 7.08-7.06 (m, 2H), 3.95 (dd, *J* = 8.0, 6.6 Hz, 1H), 3.53 – 3.47 (m, 1H), 3.34 – 3.28 (m, 1H), 2.93 – 2.85 (m, 1H), 2.82 -2.75 (m, 1H), 2.73 – 2.69 (m, 2H), 2.51 – 2.42 (m, 1H), 2.17 – 2.09 (m, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 208.5, 140.7, 137.3, 129.1, 128.4, 128.4, 128.2, 127.6, 126.0, 55.4, 43.2, 42.9, 34.3, 29.8.

FT-IR (film): 3027, 2925, 1712, 1494, 1453, 1074, 1030, 749, 699 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₈H₁₉ClNa: 309.1017, found: 309.1013.

 $[\alpha]^{25}D = +197.2$ (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



1-(2,3-Dihydro-1*H***-inden-1-yl)-3-phenylpropan-1-one (Fig. 2, compound 45).** The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 2,3-dihydro-1*H*-indene. The product was purified by column chromatography on silica gel (1:9 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 91 mg, 73% yield, 82% ee; (R)-L: 85 mg, 68% yield, 81% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 6.8 min (major), 7.4 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 7.31 – 7.26 (m, 3H), 7.24 – 7.15 (m, 6H), 4.10 (t, *J* = 7.0 Hz, 1H), 3.12 – 3.05 (m, 1H), 2.98 – 2.90 (m, 3H), 2.89 – 2.81 (m, 2H), 2.30 (q, *J* = 6.8 Hz, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 209.7, 144.5, 141.1, 140.8, 128.4, 128.3, 127.5, 126.4, 126.0, 124.9, 124.7, 58.3, 42.0, 31.9, 29.8, 28.5.

FT-IR (film): 3025, 2932, 1708, 1496, 1454, 1360, 1180, 1142, 1075, 1027, 749, 699 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₈H₁₈ONa: 273.1250, found: 273.1247.

 $[\alpha]^{25}$ D = -10.8 (*c* 1.0, CH₂Cl₂); 82% ee from (*S*)-L.



tert-Butyl 5-(3-oxo-5-phenylpentan-2-yl)-1*H*-indole-1-carboxylate (Fig. 2, compound 46). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and *tert*-butyl 5-ethyl-1*H*-indole-1-carboxylate. The product was purified by column chromatography on silica gel (1:40 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 140 mg, 74% yield, 95% ee; (*R*)-L: 136 mg, 72% yield, 95% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 6.5 min (minor), 7.3 min (major).

¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, *J* = 8.6 Hz, 1H), 7.60 (d, *J* = 3.8 Hz, 1H), 7.34 (d, *J* = 2.0 Hz, 1H), 7.22 – 7.18 (m, 2H), 7.16 – 7.11 (m, 2H), 7.07 – 7.04 (m, 2H), 6.52 (d, *J* = 3.7 Hz, 1H), 3.80 (q, *J* = 7.0 Hz, 1H), 2.90 – 2.61 (m, 4H), 1.68 (s, 9H), 1.43 (d, *J* = 6.8 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 210.1, 149.6, 141.0, 134.9, 134.3, 131.1, 128.3, 128.2, 126.4, 125.9, 124.1, 120.0, 115.5, 107.1, 83.7, 53.0, 42.4, 30.0, 28.1, 17.6.

FT-IR (film): 2976, 1731, 1469, 1371, 1348, 1256, 1161, 1082, 1023, 728, 698 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₄H₂₇NO₃Na: 400.1883, found: 400.1879.

 $[\alpha]^{25}$ _D = -77.5 (*c* 1.0, CH₂Cl₂); 95% ee from (*R*)-L.



4-(4-Isobutylphenyl)-1-phenylpentan-3-one (Fig. 3, compound 47). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 4-(4-isobutylphenyl)-1-phenylpentan-3-one. The product was purified by column chromatography on silica gel (1:100 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 91 mg, 62% yield, 94% ee; (R)-L: 88 mg, 60% yield, 95% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 7.6 min (major), 8.7 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.21 – 7.17 (m, 2H), 7.14 – 7.10 (m, 1H), 7.07 – 7.02 (m, 6H), 3.66 (q, *J* = 7.0 Hz, 1H), 2.86 – 2.58 (m, 4H), 2.43 (d, *J* = 7.1 Hz, 2H), 1.87 – 1.79 (m, 1H), 1.35 (d, *J* = 7.0 Hz, 3H), 0.89 (d, *J* = 6.6 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 209.9, 141.0, 140.5, 137.6, 129.5, 128.3, 128.2, 128.2, 127.5, 125.9, 52.7, 44.9, 42.4, 30.1, 29.9, 22.3, 17.2.

FT-IR (film): 2955, 2868, 1713, 1510, 1453, 1366, 1180, 1128, 1075, 1020, 846, 748, 699 cm⁻¹. HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₁H₂₆ONa: 341.1512, found: 341.1508. $[\alpha]^{25}$ D = +99.5 (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



4-(3-Phenoxyphenyl)-1-phenylpentan-3-one (Fig. 3, compound 48). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 1-ethyl-3-phenoxybenzene. The product was purified by column chromatography on silica gel (1:30 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 121 mg, 73% yield, 93% ee; (*R*)-L: 127 mg, 77% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 6.2 min (major), 6.7 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 7.41 – 7.35 (m, 2H), 7.33 – 7.27 (m, 3H), 7.24 – 7.19 (m, 1H), 7.18 – 7.13 (m, 3H), 7.07 – 7.04 (m, 2H), 6.97 – 6.92 (m, 3H), 3.72 (q, *J* = 7.0 Hz, 1H), 2.96 – 2.82 (m, 2H), 2.80 – 2.67 (m, 2H), 1.43 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 209.2, 157.6, 156.8, 142.3, 140.9, 130.0, 129.7, 1283, 128.1, 125.9, 123.3, 122.5, 118.8, 118.3, 117.2, 52.8, 42.4, 29.8, 17.1.

FT-IR (film): 3026, 2927, 1712, 1581, 1484, 1243, 1142, 1075, 924, 750, 692 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₃H₂₂O₂Na: 353.1512, found: 353.1508.

 $[\alpha]^{25}$ D = +89.3 (*c* 1.0, CH₂Cl₂); 93% ee from (*S*)-L.



3-(3-Benzoylphenyl)butan-2-one (Fig. 3, compound 49). The title compound was synthesized according to **GP-B** from acetic acid and (3-ethylphenyl)(phenyl)methanone. The product was purified by column chromatography on silica gel (1:10 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 108 mg, 85% yield, 94% ee; (*R*)-L: 105 mg, 83% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 11.9 min (minor), 12.4 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.56 – 7.52 (m, 2H), 7.47 – 7.45 (m, 1H), 7.44 – 7.41 (m, 1H), 7.36 – 7.32 (m, 1H), 7.25 – 7.18 (m, 4H), 3.61 (q, *J* = 7.0 Hz, 1H), 1.85 (s, 3H), 1.19 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 207.9, 196.1, 140.7, 138.0, 137.2, 132.4, 131.5, 129.8, 129.2, 128.8, 128.7, 128.1, 53.2, 28.3, 17.1.

FT-IR (film): 2927, 1707, 1654, 1596, 1446, 1383, 1276, 1163, 786, 701, 634 cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₁₇H₁₆O₂Na: 275.1043, found: 275.1039. [α]²⁵D = +113.9 (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



4-(6-Methoxynaphthalen-2-yl)-1-phenylpentan-3-one (Fig. 3, compound 50). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 2-ethyl-6-methoxynaphthalene. The product was purified by column chromatography on silica gel (1:100 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 105 mg, 66% yield, 93% ee; (R)-L: 109 mg, 68% yield, 92% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 10.6 min (major), 11.6 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.64 (t, *J* = 9.3 Hz, 2H), 7.50 (s, 1H), 7.21 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.17 – 7.12 (m, 3H), 7.10 – 7.07 (m, 2H), 7.01 (d, *J* = 6.9 Hz, 2H), 3.85 (s, 3H), 3.79 (q, *J* = 7.0 Hz, 1H), 2.86 – 2.79 (m, 1H), 2.77 – 2.71 (m, 1H), 2.70 – 2.61 (m, 2H), 1.43 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 209.8, 157.6, 140.9, 135.5, 133.5, 129.1, 129.0, 128.2, 128.1, 127.4, 126.4, 126.2, 125.8, 119.0, 105.5, 55.1, 52.9, 42.4, 29.8, 17.2.

FT-IR (film): 2927, 1707, 1604, 1389, 1261, 1030, 849, 739, 696 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₂H₂₂O₂Na: 341.1512, found: 341.1508.

 $[\alpha]^{25}$ D = +115.9 (*c* 1.0, CH₂Cl₂); 93% ee from (*S*)-L.



Methyl 4'-(3-oxo-1-phenylnonan-4-yl)-[1,1'-biphenyl]-4-carboxylate (Fig. 3, compound 51). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and methyl 4'-hexyl-[1,1'-biphenyl]-4-carboxylate. The product was purified by column chromatography on silica gel (1:10 EtOAc/Petroleum ether). White solid (mp = 67-69 °C).

(S)-L: 155 mg, 72% yield, 92% ee; (R)-L: 159 mg, 74% yield, 92% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.7 min (major), 9.9 min (minor).

¹H NMR (400 MHz, CDCl₃) δ 8.09 (d, *J* = 8.4 Hz, 2H), 7.63 (d, *J* = 8.4 Hz, 2H), 7.53 (d, *J* = 8.2 Hz, 2H)., 7.24 (d, *J* = 8.3 Hz, 2H), 7.21 – 7.17 (m, 2H), 7.15 – 7.10 (m, 1H), 7.07 – 7.05 (m, 2H), 3.91 (s, 3H), 3.62 (t, *J* = 7.4 Hz, 1H), 2.90 – 2.77 (m, 2H), 2.76 – 2.66 (m, 2H), 2.09 – 2.00 (m, 1H), 1.75 – 1.66 (m, 1H), 1.27 – 1.12 (m, 6H), 0.92 – 0.80 (t, *J* = 6.7 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 209.2, 166.8, 144.9, 140.8, 138.9, 138.6, 130.0, 128.8, 128.7, 128.3, 128.2, 127.5, 126.8, 125.9, 58.8, 52.0, 43.3, 31.9, 31.6, 29.7, 27.1, 22.3, 13.9.

FT-IR (film): 2927, 2856, 1718, 1607, 1434, 1278, 1110, 1005, 828, 772, 699 cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₂₉H₃₂O₃Na: 451.2244, found: 451.2241. [α]²⁵_D = +70.5 (*c* 1.0, CH₂Cl₂); 92% ee from (*S*)-L.



(1*R*,2*S*,5*R*)-2-Isopropyl-5-methylcyclohexyl 4-(3-oxo-5-phenylpentan-2-yl)benzoate (Fig. 3, compound 52 & 53). The title compound was synthesized according to GP-B from lithocholic acid and (1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl 4-(3-oxo-5-phenylpentan-2-yl)benzoate. The product was purified by column chromatography on silica gel (1:60 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 147 mg, 70% yield, 4:96 dr;

(*R*)-L: 143 mg, 70% yield, 96:4 dr.

HPLC analysis: The dr was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 12.9 min (minor), 15.0 min (major).

NMR data for the product from (*S*)-L:

¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, *J* = 7.1 Hz, 2H), 7.21 (t, *J* = 6.9 Hz, 4H), 7.17 – 7.13 (m, 1H), 7.06 (d, *J* = 7.4 Hz, 2H), 4.93 (td, *J* = 10.8, 3.8 Hz, 1H), 3.76 (q, *J* = 6.9 Hz, 1H), 2.89 – 2.75 (m, 2H), 2.67 (t, *J* = 7.5 Hz, 2H), 2.12 (d, *J* = 12.0 Hz, 1H), 1.99 – 1.91 (m, 1H), 1.73 (d, *J* = 11.0 Hz, 2H), 1.59 – 1.52 (m, 3H), 1.39 (d, *J* = 6.8 Hz, 3H), 1.18 – 1.05 (m, 2H), 0.93 (t, *J* = 4.8 Hz, 6H), 0.80 (d, *J* = 6.8 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 208.8, 165.6, 145.2, 140.7, 130.1, 129.7, 128.3, 128.2, 127.8, 126.0, 74.7, 53.1, 47.2, 42.7, 40.9, 34.2, 31.4, 29.8, 26.4, 23.5, 22.0, 20.7, 17.2, 16.4.

NMR data for the product from (*R*)-L:

¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, *J* = 7.2 Hz, 2H), 7.23 – 7.19 (m, 4H), 7.17 – 7.13 (m, 1H), 7.06 (d, *J* = 7.7 Hz, 2H), 4.93 (td, *J* = 10.7, 4.1 Hz, 1H), 3.76 (q, *J* = 6.9 Hz, 1H), 2.89 – 2.76 (m, 2H), 2.67 (t, *J* = 7.3 Hz, 2H), 2.11 (d, *J* = 12.2 Hz, 1H), 2.00 – 1.92 (m, 1H), 1.73 (d, *J* = 11.1 Hz, 2H), 1.60 – 1.52 (m, 3H), 1.38 (d, *J* = 6.8 Hz, 3H), 1.19 – 1.05 (m, 2H), 0.93 (d, *J* = 6.8 Hz, 6H), 0.80 (d, *J* = 6.8 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 208.7, 165.6, 145.1, 140.7, 130.1, 129.6, 128.3, 128.1, 127.7, 125.9, 74.7, 53.0, 47.1, 42.6, 40.8, 34.2, 31.3, 29.7, 26.4, 23.5, 21.9, 20.7, 17.2, 16.4.

FT-IR (film): 3026, 2927, 1712, 1581, 1484, 1442, 1243, 1142, 1075, 924, 750, 692 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₈H₃₆O₃Na: 443.2557, found: 443.2553.

 $[\alpha]^{25}$ _D = +11.4 (*c* 1.0, CH₂Cl₂); 4:96 dr from (*S*)-L.

 $[\alpha]^{25}$ _D = -119.0 (*c* 1.0, CH₂Cl₂); 96:4 dr from (*R*)-L.



Methyl (2*R*)-2-((*tert*-butoxycarbonyl)amino)-5-oxo-4,7-diphenylheptanoate (Fig. 3, compound 54 & 55). The title compound was synthesized according to GP-B from lithocholic acid and methyl methyl (*R*)-2-((*tert*-butoxycarbonyl)amino)-4-phenylbutanoate. The product was purified by column chromatography on silica gel (1:5 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 98 mg, 46% yield, 3:97 dr;

(*R*)-L: 93 mg, 44% yield, 99:1 dr.

HPLC analysis: The dr was determined via HPLC on a CHIRALPAK AD-3 column (10.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 16.6 min (minor), 18.6 min (major).

NMR data for the product from (*S*)-L:

¹H NMR (400 MHz, CDCl₃) δ 7.32 – 7.24 (m, 3H), 7.23 – 7.18 (m, 2H), 7.17 – 7.12 (m, 3H), 7.04 – 7.02 (m, 2H), 4.98 (d, *J* = 8.9 Hz, 1H), 4.14 (s, 1H), 3.75 (t, *J* = 7.0 Hz, 1H), 3.66 (s, 3H), 2.88 – 2.73 (m, 2H), 2.72 – 2.65 (m, 2H), 2.43 (s, 1H), 2.21 – 2.14 (m, 1H), 1.44 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 208.3, 172.9, 155.2, 140.6, 137.5, 129.0, 128.2, 128.1, 127.5, 125.9, 79.8, 55.4, 52.1, 43.0, 34.4, 29.7, 28.2.

NMR data for the product from (*R*)-L:

¹H NMR (400 MHz, CDCl₃) δ 7.30 – 7.27 (m, 1H), 7.26 – 7.23 (m, 2H), 7.21 – 7.17 (m, 2H), 7.15 – 7.11 (m, 3H), 7.05 – 7.03 (m, 2H), 5.09 (s, 1H), 4.30 (s, 1H), 3.78 (dd, *J* = 8.9, 5.3 Hz, 1H), 3.65 (s, 3H), 2.91 – 2.83 (m, 1H), 2.78 – 2.61 (m, 4H), 1.79 (s, 1H), 1.45 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 207.8, 172.7, 155.4, 140.9, 137.9, 129.0, 128.2, 128.2, 127.5, 125.8, 79.9, 54.8, 52.2, 51.9, 43.0, 35.6, 29.6, 28.2.

FT-IR (film): 2928, 1713, 1496, 1365, 1250, 1163, 1049, 748, 700 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₅H₃₁NO₅Na: 448.2094, found: 448.2090.

 $[\alpha]^{25}D = +98.0$ (*c* 1.0, CH₂Cl₂); 3:97 dr from (*S*)-L.

 $[\alpha]^{25}$ D = -148.7 (*c* 1.0, CH₂Cl₂); 99:1 dr from (*R*)-L.



4-([1,1'-Biphenyl]-4-yl)-1-(4,5-diphenyloxazol-2-yl)pentan-3-one (Fig. 3, compound 56). The title compound was synthesized according to **GP-B** from 3-(4,5-diphenyloxazol-2-yl)propanoic acid and 4-ethyl-1,1'-biphenyl. The product was purified by column chromatography on silica gel (1:5 EtOAc/Petroleum ether). Light green oil.

(*S*)-L: 180 mg, 78% yield, 87% ee; (*R*)-L: 176 mg, 77% yield, 88% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (10.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 7.9 min (major), 8.9 min (minor).

¹H NMR (400 MHz, CDCl₃) δ δ 7.60 – 7.58 (m, 2H), 7.57 – 7.53 (m, 6H), 7.45 – 7.42 (m, 2H), 7.36 – 7.30 (m, 9H), 3.92 (q, *J* = 5.6 Hz, 1H), 3.18 – 3.12 (m, 1H), 3.09 – 3.06 (m, 1H), 3.05 – 3.00 (m, 2H), 1.49 (dd, 5.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 208.5, 162.3, 145.2, 140.6, 140.2, 139.3, 135.0, 132.5, 129.0, 128.7, 128.6, 128.5, 128.33, 128.28, 128.0, 127.8, 127.7, 127.3, 127.0, 126.4, 52.6, 37.6, 22.4, 17.5.

FT-IR (film): 2922, 1712, 1570, 1484, 1384, 1054, 960, 838, 761, 693 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₃₂H₂₇NO₂Na: 480.1934, found: 480.1930.

 $[\alpha]^{25}$ = +67.1 (*c* 1.0, CH₂Cl₂); 87% ee from (*S*)-L.



2-([1,1'-Biphenyl]-4-yl)icosan-3-one (Fig. 3, compound 57). The title compound was synthesized according to **GP-B** from stearic acid and 4-ethyl-1,1'-biphenyl. The product was purified by column chromatography on silica gel (1:600 EtOAc/Petroleum ether). White solid (mp = 63-65 °C).

(S)-L: 208mg, 93% yield, 90% ee; (R)-L: 201 mg, 90% yield, 90% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 4.4 min (minor), 5.1 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.60 – 7.54 (m, 4H), 7.45 – 7.42 (m, 2H), 7.36 – 7.32 (m, 1H), 7.29 (d, *J* = 8.2 Hz, 2H), 3.80 (q, *J* = 7.0 Hz, 1H), 2.41 – 2.37 (m, 2H), 1.53 – 1.46 (m, 2H), 1.43 (d, *J* = 7.0 Hz, 3H), 1.32 – 1.16 (m, 28H), 0.88 (t, *J* = 6.9 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 211.1, 140.6, 140.0, 139.8, 128.8, 128.3, 127.5, 127.3, 127.0, 52.6, 41.1, 31.9, 29.7, 29.6, 29.6, 29.4, 29.4, 29.3, 29.1, 23.9, 22.7, 17.5, 14.1.

FT-IR (film): 2921, 2850, 1710, 1471, 1406, 848, 762, 724 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₃₂H₄₈ONa: 471.3597, found: 471.3593.

 $[\alpha]^{25_{\rm D}}$ = +92.5 (*c* 1.0, CH₂Cl₂); 90% ee from (*S*)-L.



(*Z*)-2-([1,1'-Biphenyl]-4-yl)icos-11-en-3-one (Fig. 3, compound 58). The title compound was synthesized according to **GP-B** from oleic acid and 4-ethyl-1,1'-biphenyl. The product was purified by column chromatography on silica gel (1:400 EtOAc/Petroleum ether). White solid (mp = 39-41 °C).

(S)-L: 93 mg, 41% yield, 94% ee; (R)-L: 87 mg, 39% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (10.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 3.9 min (minor), 4.3 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.59 – 7.56 (m, 3H), 7.55 (t, *J* = 1.9 Hz, 1H), 7.45 – 7.42 (m, 2H), 7.36 – 7.33 (m, 1H), 7.30 – 7.28 (m, 2H), 5.36 – 5.34 (m, 2H), 3.80 (q, *J* = 7.0 Hz, 1H), 2.41 – 2.37 (m, 2H), 2.00 – 1.90 (m, 4H), 1.56 – 1.47 (m, 2H), 1.43 (d, *J* = 7.0 Hz, 3H), 1.33 – 1.26 (m, 14H), 1.23 – 1.18 (m, 6H), 0.88 (t, *J* = 6.9 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 211.0, 140.6, 140.00, 139.76, 130.4, 130.2, 128.8, 128.3, 127.5, 127.3, 127.0, 52.6, 41.1, 32.6, 32.5, 31.9, 29.6, 29.5, 29.5, 29.3, 29,182, 29.176, 29.0, 28.9, 23.9, 22. 7, 17.5, 14.1. FT-IR (film): 2924, 2852, 1715, 1486, 1456, 1180, 1131, 1075, 1007, 967, 840, 763, 731, 696 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₃₂H₄₆ONa: 469.3441, found: 469.3443.

 $[\alpha]^{25}$ _D = +101.2 (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



3-([1,1'-Biphenyl]-4-yl)-1-(2,4-dichlorophenoxy)butan-2-one (Fig. 3, compound 59). The title compound was synthesized according to **GP-B** from 2-(2,4-dichlorophenoxy)acetic acid and 4-ethylbiphenyl. The product was purified by column chromatography on silica gel (1:15 EtOAc/Petroleum ether). White solid (mp = 105-107 °C).

(S)-L: 73 mg, 38% yield, 87% ee; (R)-L: 77 mg, 40% yield, 86% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.0 min (major), 8.7 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.57 – 7.54 (m, 4H), 7.45 – 7.42 (m, 2H), 7.38 (d, *J* = 2.5 Hz, 1H), 7.37 – 7.34 (m, 3H), 7.05 (dd, *J* = 8.8, 2.5 Hz, 1H), 6.49 (d, *J* = 8.8 Hz, 1H), 4.59 (s, 2H), 4.25 (q, *J* = 7.0 Hz, 1H), 1.49 (d, *J* = 7.0 Hz, 3H).
¹³C NMR (126 MHz, CDCl₃) δ 205.8, 152.1, 140.4, 140.4, 138.1, 130.2, 128.8, 128.5, 127.7, 127.5, 127.4, 127.0, 126.7, 123.8, 113.9, 72.1, 48.4, 17.1.

FT-IR (film): 2971, 2900, 1718, 1476, 1384, 1242, 1196, 1180, 1075, 1052, 840, 731, 695 cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₂₂H₁₈C₁₂O₂Na: 407.0576, found: 407.0578. [α]²⁵_D = +105.2 (*c* 1.0, CH₂Cl₂); 87% ee from (*S*)-L.



(6*R*)-2-([1,1'-Biphenyl]-4-yl)-6-((3*R*,8*R*,9*S*,10*S*,13*R*,14*S*,17*R*)-3-((*tert*-

butyldimethylsilyl)oxy)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-

yl)heptan-3-one (Fig. 3, compound 60 & 61). The title compound was synthesized according to **GP-B** from lithocholic acid and 4-ethyl-1,1'-biphenyl. The product was purified by column chromatography on silica gel (1:400 EtOAc/Petroleum ether). White solid (mp = 101-102 °C).

(*S*)-L: 295 mg, 84% yield, 4:96 dr;

(*R*)-L: 300 mg, 85% yield, 96:4 dr.

HPLC analysis: The dr was determined via HPLC on a CHIRALCEL OD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 4.0 min (minor), 4.2 min (major).

NMR data for the product from (*S*)-L:

¹H NMR (500 MHz, CDCl₃) δ 7.61 – 7.57 (m, 4H), 7.46 – 7.43 (m, 2H), 7.36 – 7.30 (m, 3H), 3.82 (q, *J* = 6.9 Hz, 1H), 3.63 – 3.57 (m, 1H), 2.48 – 2.42 (m, 1H), 2.35 – 2.28 (m, 1H), 1.92 – 1.89 (m, 1H), 1.86 – 1.79 (m, 2H), 1.77 – 1.70 (m, 3H), 1.58 – 1.50 (m, 2H), 1.45 (d, *J* = 7.0 Hz, 3H), 1.42 – 1.29 (m, 8H), 1.26 – 1.07 (m, 6H), 1.05 – 1.00 (m, 3H), 0.98 – 0.96 (m, 1H), 0.92 (s, 9H), 0.91 (s, 3H), 0.82 (d, *J* = 6.6 Hz, 3H), 0.61 (s, 3H), 0.09 (s, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 211.4, 140.6, 140.0, 139.7, 128.7, 128.3, 127.5, 127.2, 127.0, 72.8, 56.3, 55.9, 52.7, 42.6, 42.2, 40.2, 40.1, 37.9, 36. 9, 35.8, 35.5, 35.2, 34.5, 31.0, 30.1, 28.0, 27.3, 26.3, 25.9, 24.1, 23.3, 20.8, 18.4, 18.3, 17.5, 12.0, -4.6.

NMR data for the product from (*R*)-L:

¹H NMR (500 MHz, CDCl₃) δ 7.59 (t, *J* = 8.1 Hz, 4H), 7.44 (t, *J* = 6.2 Hz, 2H), 7.36 – 7.30 (m, 3H), 3.83 (q, *J* = 6.3 Hz, 1H), 3.63 – 3.57 (m, 1H), 2.41 – 2.36 (m, 2H), 1.90 – 1.67 (m, 7H), 1.58 – 1.34 (m, 12H), 1.29 – 1.18 (m, 5H), 1.15 – 1.07 (m, 2H), 1.04 – 1.01 (m, 3H), 0.92 (s, 9H), 0.91 (s, 3H), 0.76 (s, 3H), 0.59 (s, 3H), 0.09 (s, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 211.1, 140.6, 139.9, 139.7, 128.7, 128.2, 127.5, 127.2, 126.9, 72.7, 56.3, 56.0, 52.5, 42.6, 42.2, 40.1, 40.0, 38.0, 36.8, 35.8, 35.5, 35.1, 34.5, 31.0, 30.0, 28.1, 27.2, 26.3, 25.9, 24.1, 23.3, 20.7, 18.23, 18.17, 17.4, 11.9, -4.6.

FT-IR (film):2927, 2857, 1714, 1486, 1449, 1372, 1250, 1094, 1077, 835, 773, 697 cm⁻¹.

HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₄₄H₆₆O₂SiNa: 677.4724, found: 677.4719. [α]²⁵_D = +82.9 (*c* 1.0, CH₂Cl₂); 4:96 dr from (*S*)-L. [α]²⁵_D = -43.6 (*c* 1.0, CH₂Cl₂); 96:4 dr from (*R*)-L.



Phenyl 3-methyl-2-phenylbutanoate (Fig. 6, compound 72). The title compound was synthesized according to **GP-E** from phenyl carbonochloridate and isobutylbenzene. The product was purified by preparative thin-layer chromatography on silica gel (1:25 EtOAc/Petroleum ether). Yellow oil.

(*S*, *R*)-L2: 107 mg, 84% yield, 98% ee; (*R*, *S*)-L2: 102 mg, 80% yield, 98% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (25.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*, *R*)-L: 7.7 min (minor), 8.7 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.47 – 7.44 (m, 2H), 7.40 – 7.31 (m, 5H), 7.23 – 7.20 (m, 1H), 7.03 – 7.01 (m, 2H), 3.43 (d, *J* = 10.5 Hz, 1H), 2.54 – 2.46 (m, 1H), 1.22 (d, *J* = 6.5 Hz, 3H), 0.82 (d, *J* = 6.7 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 172.4, 150.7, 137.8, 129.3, 128.6, 128.6, 127.4, 125.7, 121.4, 60.0, 32.0, 21.5, 20.2.

FT-IR (film): 2961, 2871, 1754, 1492, 1287, 1195, 1105, 750, 698 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₇H₁₈O₂Na: 277.1199, found: 277.1198.

 $[\alpha]^{25}D = +68.0$ (*c* 1.0, CH₂Cl₂); 98% ee from (*S*, *R*)-L.



Phenyl 2-([1,1'-biphenyl]-4-yl)butanoate (Fig. 6, compound 73). The title compound was synthesized according to **GP-E** from phenyl carbonochloridate and 4-propyl-1,1'-biphenyl. The product was purified by preparative thin-layer chromatography on silica gel (1:25 EtOAc/Petroleum ether). Yellow solid (mp = 66-67 °C).

(*S*, *R*)-L2: 138 mg, 87% yield, 91% ee; (*R*, *S*)-L2: 142 mg, 90% yield, 90% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*, *R*)-L: 24.0 min (major), 29.7 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.64 – 7.62 (m, 4H), 7.51 – 7.45 (m, 4H), 7.39 – 7.35 (m, 3H), 7.22 (t, *J* = 7.5 Hz, 1H), 7.04 (d, *J* = 7.7 Hz, 2H), 3.78 (t, *J* = 7.7 Hz, 1H), 2.34 – 2.25 (m, 1H), 2.02 – 1.93 (m, 1H), 1.06 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 172.5, 150.6, 140.7, 140.3, 137.6, 129.3, 128.8, 128.4, 127.4, 127.3, 127.0, 125.8, 121.4, 53.2, 26.8, 12.2.

FT-IR (film): 2965, 2929, 1754, 1592, 1486, 1193, 1139, 839, 757, 697 cm⁻¹.

HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₂₂H₂₀O₂Na: 339.1356, found: 339.1353. [α]²⁵_D = +98.4 (*c* 1.0, CH₂Cl₂); 91% ee from (*S*, *R*)-L.



Phenyl 4-methyl-2-phenylpentanoate (Fig. 6, compound 74). The title compound was synthesized according to **GP-E** from phenyl carbonochloridate and isopentylbenzene. The product was purified by preparative thin-layer chromatography on silica gel (1:25 EtOAc/Petroleum ether). Yellow oil.

(*S*, *R*)-L2: 103 mg, 76% yield, 83% ee; (*R*, *S*)-L2: 93 mg, 69% yield, 81% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (25.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*, *R*)-L: 6.1 min (major), 7.1 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.45 – 7.43 (m, 2H), 7.40 – 7.30 (m, 5H), 7.22 – 7.19 (m, 1H), 7.01 – 6.99 (m, 2H), 3.92 (t, *J* = 7.8 Hz, 1H), 2.15 – 2.10 (m, 1H), 1.84 – 1.78 (m, 1H), 1.66 – 1.58 (m, 1H), 1.00 (d, *J* = 6.6 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 172.7, 150.8, 138.9, 129.3, 128.7, 128.0, 127.4, 125.7, 121.4, 49.7, 42.4, 26.0, 22.6, 22.3.

FT-IR (film): 2956, 2928, 1755, 1592, 1492, 1455, 1195, 1114, 747, 697 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₈H₂₀O₂Na: 291.1356, found: 291.1355.

 $[\alpha]^{25}$ D = +66.5 (*c* 1.0, CH₂Cl₂); 83% ee from (*S*, *R*)-L.



Phenyl 2-phenylpropanoate (Fig. 6, compound 75). The title compound was synthesized according to **GP-E** from phenyl carbonochloridate and ethylbenzene. The product was purified by preparative thin-layer chromatography on silica gel (1:25 EtOAc/Petroleum ether). Yellow oil.

(*S*, *R*)-**L2**: **6**3 mg, 56% yield, 83% ee; (*R*, *S*)-**L2**: **70** mg, 61% yield, 83% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (25.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (S, R)-L: 19.0 min (minor), 20.5 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.45 – 7.29 (m, 7H), 7.23 – 7.19 (m, 1H), 7.03 – 7.00 (m, 2H), 3.99 (q, *J* = 7.1 Hz, 1H), 1.64 (d, *J* = 7.2 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 173.0, 150.8, 140.1, 129.3, 128.8, 127.5, 127.3, 125.7, 121.3, 45.6, 18.5.

FT-IR (film): 2979, 2919, 1754, 1591, 1491, 1195, 1138, 1071, 746, 690 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₅H₁₄O₂Na: 249.0886, found: 249.0883.

 $[\alpha]^{25}$ _D = +74.4 (*c* 1.0, CHCl₃); 83% ee from (*S*, *R*)-L.

IV. Synthetic Utility: Gram Scale Synthesis and Parallel Synthesis

A) Gram scale synthesis (20.0 mmol scale):



General Procedure F (GP-F): In a glovebox, a 1000 mL flask, equipped with a Teflon stir bar, was charged with Ir[dF(CF₃)ppy]₂(dtbbyy)PF₆ (0.22 g, 0.2 mmol, 1.0%), NiBr₂·glyme (0.62 g, 2.0 mmol, 10.0%), (*S*)-L (0.94 g, 2.6 mmol, 13.0%), NH₄Cl (1.06 g, 20.0 mmol, 1.0 equiv), Na₂HPO₄ (4.24 g, 30.0 mmol, 1.0 equiv), anhydrous *i*-PrOAc (200.0 mL), and the 4-ethylbiphenyl (10.94 g, 60.0 mmol, 3.0 equiv) was added, and followed by the addition of lithocholic acid (9.82 g, 20.0 mmol, 1.0 equiv) as a solid. Then, DMDC (3.20 mL, 30.0 mmol, 1.5 equiv) was added dropwise via a syringe. The flask was closed with a rubber stopper and wrapped with electrical tape. Next, the reaction mixture was transferred out of the glovebox, and then vacuum grease was liberally applied to cover the punctures in the septum cap. Then, the reaction mixture was stirred at 10°C in an EtOH bath for 5 min before irradiation. The reaction was stirred at 10 °C for 25 hours under blue LED irradiation with 3*40 W blue LED lamps (Kessil PR160L, 427 nm). The reaction mixture was then passed through a short pad of silica gel, with Et₂O as the eluent (~400 mL). The resulting mixture was concentrated, and the residue was purified by flash chromatography on silica gel (1:200 EtOAc/Petroleum ether). White solid.

(*S*)-L: 9.13 g, 70% yield, 5:95 dr.



The procedure is the same as **GP-F**, except for the use of 6-bromohexanoic acid (3.90 g, 20.0 mmol, 1.0 equiv) instead of lithocholic acid.

(*S*)-L: 5.35 g, 75% yield, 92% ee

B) Parallel synthsis of drug analogues (>100 mg product in all cases):



3-(2-Fluoro-[1,1'-biphenyl]-4-yl)butan-2-one (Fig. 4, compound 62). The title compound was synthesized according to **GP-B** from acetic acid and 4-ethyl-2-fluoro-1,1'-biphenyl. The product was purified by column chromatography on silica gel (1:40 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 108 mg, 89% yield, 94% ee; (*R*)-L: 104 mg, 86% yield, 94% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 10.6 min (minor), 12.6 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, *J* = 7.7 Hz, 2H), 7.47 – 7.43 (m, 3H), 7.41 – 7.36 (m, 1H), 7.11 – 7.04 (m, 2H), 3.80 (q, *J* = 7.0 Hz, 1H), 2.13 (s, 3H), 1.45 (d, *J* = 7.0 Hz, 3H).

¹⁹F NMR (471 MHz, CDCl₃) δ -117.3 (s, 1F).

 13 C NMR (126 MHz, CDCl₃) δ 208.2, 159.8 (d, *J*_{C-F} = 249.3 Hz), 141.8 (d, *J*_{C-F} = 7.7 Hz), 135.3, 131.1 (d, *J*_{C-F} = 4.1 Hz), 128.9 (d, *J*_{C-F} = 2.7 Hz), 128.4, 127.9, 127.85, 127.7, 123.8 (d, *J*_{C-F} = 3.2 Hz), 115.4 (d, *J*_{C-F} = 23.2 Hz), 53.0, 28.5, 17.1.

FT-IR (film): 2977, 2931, 1716, 1622, 1483, 1417, 1355, 1267, 1173, 1130, 919, 767, 698 cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₁₆H₁₅FONa: 265.0999, found: 265.0997. [α]²⁵D = +171.1 (*c* 1.0, CH₂Cl₂); 94% ee from (*S*)-L.



2-(2-Fluoro-[1,1'-biphenyl]-4-yl)hexan-3-one (Fig. 4, compound 63). The title compound was synthesized according to **GP-B** from butyric acid and 4-ethyl-2-fluoro-1,1'-biphenyl. The product was purified by column chromatography on silica gel (1:40 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 121 mg, 90% yield, 91% ee; (*R*)-L: 119 mg, 88% yield, 92% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 5.8 min (minor), 6.2 min (major).

¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, *J* = 7.5 Hz, 2H), 7.46 – 7.35 (m, 4H), 7.08 – 7.03 (m, 2H), 3.79 (q, *J* = 7.0 Hz, 1H), 2.41 (t, *J* = 7.2 Hz, 2H), 1.63 – 1.52 (m, 2H), 1.43 (d, *J* = 7.0 Hz, 3H), 0.85 (t, *J* = 7.5 Hz, 3H).

¹⁹F NMR (471 MHz, CDCl₃) δ -117.4 (s, 1F).

¹³C NMR (126 MHz, CDCl₃) δ 210.3, 159.7 (d, *J*_{C-F} = 249.3 Hz), 142.0 (d, *J*_{C-F} = 7.7 Hz), 135.3, 131.0 (d, *J*_{C-F} = 4.1 Hz), 128.9 (d, *J*_{C-F} = 2.7 Hz), 128.4, 127.70, 127.66, 127.6, 123.8 (d, *J*_{C-F} = 3.2 Hz), 115.5 (d, *J*_{C-F} = 23.2 Hz), 52.2, 43.1, 17.4, 17.1, 13.6.

FT-IR (film): 2963, 2874, 1714, 1581, 1483, 1416, 1266, 1130, 1011, 921, 875, 766, 697 cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₁₈H₁₉FONa: 293.1312, found: 293.1309. [α]²⁵_D = +139.4 (*c* 1.0, CH₂Cl₂); 91% ee from (*S*)-L.



4-(3-Fluoro-[1,1'-biphenyl]-4-yl)-1-phenylpentan-3-one (Fig. 4, compound 64). The title compound was synthesized according to **GP-B** from 3-phenylpropanoic acid and 4-ethyl-3-fluoro-1,1'-biphenyl. The product was purified by column chromatography on silica gel (1:80 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 133 mg, 80% yield, 91% ee; (R)-L: 129 mg, 77% yield, 92% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 6.5 min (major), 6.8 min (minor).

¹H NMR (500 MHz, CDCl₃) δ 7.54 – 7.51 (m, 2H), 7.46 – 7.43 (m, 2H), 7.39 – 7.34 (m, 2H), 7.26 – 7.22 (m, 2H), 7.18 – 7.15 (m, 1H), 7.10 – 7.09 (m, 2H), 7.01 – 6.94 (m, 2H), 3.74 (q, *J* = 7.0 Hz, 1H), 2.91 – 2.81 (m, 2H), 2.80 – 2.68 (m, 2H), 1.41 (d, *J* = 7.0 Hz, 3H).

¹⁹F NMR (471 MHz, CDCl₃) δ -116.9 (s, 1F).

¹³C NMR (126 MHz, CDCl₃) δ 208.8, 159.7 (d, *J*_{C-F} = 249.6 Hz), 141.5 (d, *J*_{C-F} = 7.6 Hz), 140.7, 135.2, 130.9 (d, *J*_{C-F} = 3.9 Hz), 128.8 (d, *J*_{C-F} = 2.8 Hz), 128.33, 128.27, 128.2, 127.7, 127.6, 125.9, 123.7 (d, *J*_{C-F} = 3.3 Hz), 115.4 (d, *J*_{C-F} = 23.3 Hz), 52.4, 42.5, 29.7, 17.1.

FT-IR (film): 3028, 2975, 1715, 1622, 1483, 1453, 1416, 1266, 1131, 1066, 915, 873, 766, 697 cm⁻¹. HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₃H₂₁FONa: 355.1469, found: 355.1465.

 $[\alpha]^{25}$ D = +73.7 (*c* 1.0, CH₂Cl₂); 91% ee from (*S*)-L.



6-(2-Fluoro-[1,1'-biphenyl]-4-yl)-1-(thiophen-2-yl)heptane-1,5-dione (Fig. 4, compound 65). The title compound was synthesized according to **GP-B** from 5-oxo-5-(thiophen-2-yl)pentanoic acid and 4-ethyl-2-fluoro-1,1'-biphenyl. The product was purified by column chromatography on silica gel (1:10 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 138 mg, 73% yield, 90% ee; (*R*)-L: 134 mg, 71% yield, 90% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 15.6 min (major), 16.9 min (minor).

¹H NMR (400 MHz, CDCl₃) 8 7.66 (d, *J* = 3.7 Hz, 1H), 7.58 (d, *J* = 4.9 Hz, 1H), 7.51 (d, *J* = 8.3 Hz, 2H), 7.43 (t, *J* = 7.5 Hz, 2H), 7.39 – 7.34 (m, 2H), 7.09 – 7.00 (m, 3H), 3.80 (q, *J* = 7.0 Hz, 1H), 2.92 – 2.78 (m, 2H), 2.57 (t, *J* = 6.9 Hz, 2H), 2.05 – 1.94 (m, 2H), 1.43 (d, *J* = 7.0 Hz, 3H).

¹⁹F NMR (471 MHz, CDCl₃) δ -117.1 (s, 1F).

¹³C NMR (101 MHz, CDCl₃) δ 209.6, 192.6, 159.8 (d, *J*_{C-F} = 311.9 Hz), 144.1, 141.7 (d, *J*_{C-F} = 9.7 Hz), 135.3 (d, *J*_{C-F} = 1.1 Hz), 133.4, 131.8, 131.0 (d, *J*_{C-F} = 5.1 Hz), 128.9 (d, *J*_{C-F} = 3.7 Hz), 128.4, 128.0, 127.9, 127.7 (d, *J*_{C-F} = 17.0 Hz), 123.8 (d, *J*_{C-F} = 4.1 Hz), 115.4 (d, *J*_{C-F} = 29.4 Hz), 52.3, 39.9, 37.9, 18.5, 17.3.

FT-IR (film): 2920, 2850, 1710, 1658, 1482, 1414, 1371, 1265, 1232, 1130, 766, 697 cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₂₃H₂₁FO₂SNa: 403.1138, found: 403.1135. [α]²⁵_D = +97.9 (*c* 1.0, CH₂Cl₂); 90% ee from (*S*)-L.



tert-Butyl (5-(2-fluoro-[1,1'-biphenyl]-4-yl)-4-oxohexyl)carbamate (Fig. 4, compound 66). The title compound was synthesized according to **GP-B** from 4-((*tert*-butoxycarbonyl)amino)butanoic acid and 4-ethyl-2-fluoro-1,1'-biphenyl. The product was purified by column chromatography on silica gel (1:5 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 155 mg, 80% yield, 91% ee; (*R*)-L: 153 mg, 80% yield, 92% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (40.0% 2-PrOH in hexanes, 0.8 mL/min); retention times for compound obtained using (*S*)-L: 6.7 min (minor), 7.4 min (major).

¹H NMR (500 MHz, CDCl₃) δ 7.53 (d, *J* = 8.1 Hz, 2H), δ 7.44 (t, *J* = 7.6 Hz, 2H), 7.41 – 7.35 (m, 2H), 7.07 – 7.01 (m, 2H), 4.53 (s, 1H), 3.80 (q, *J* = 6.9 Hz, 1H), 3.09 – 2.99 (m, 2H), 2.46 (t, *J* = 7.2 Hz, 2H), 1.77 – 1.73 (m, 1H), 171 – 1.64(m, 1H), 1.43 (s, 3H), 1.41 (s, 9H).

¹⁹F NMR (471 MHz, CDCl₃) δ -117.1 (s, 1F).

¹³C NMR (126 MHz, CDCl₃) δ 209.8, 159.7 (d, *J*_{C-F} = 249.3 Hz), 155.9, 141.7 (d, *J*_{C-F} = 7.3 Hz), 135.2, 131.1 (d, *J*_{C-F} = 4.1 Hz), 128.9 (d, *J*_{C-F} = 2.7 Hz), 128.4, 127.8 (d, *J*_{C-F} = 13.7 Hz), 127.7, 123.8 (d, *J*_{C-F} = 3.2 Hz), 115.4 (d, *J*_{C-F} = 23 Hz), 79.1, 52.3, 39.7, 38.2, 28.3, 24.1, 17.3.

FT-IR (film): 2976, 2931, 1714, 1515, 1365, 1267, 1170, 767, 698 cm⁻¹. HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₃H₂₈FNO₃Na: 408.1945, found: 408.1942. [α]²⁵_D = -34.2 (*c* 1.0, CH₂Cl₂); 91% ee from (*S*)-L.



(3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-

epoxy[1,2]dioxepino[4,3-*i***]isochromen-10-yl 4-oxo-5-phenylhexanoate (Fig. 4, compound 67).** The title compound was synthesized according to **GP-C** from artesunate and ethylbenzene. The product was purified by column chromatography on silica gel (1:4 EtOAc/Petroleum ether). Yellow oil.

(*S*)-L: 169 mg, 71% yield, 98:2 dr;

(*R*)-L: 158 mg, 67% yield, 2:98 dr.

HPLC analysis: The dr was determined via HPLC on a CHIRALCEL OJ-3 column (40.0% 2-PrOH in hexanes, 0.8 mL/min); retention times for compound obtained using (*S*)-L: 23.6 min (major), 31.7 min (minor).

NMR data for the product from (*S*)-L:

¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 7.33 (t, *J* = 7.3 Hz, 2H), 7.28 – 7.24 (m, 1H), 7.22 – 7.19 (m, 2H), 6.88 (d, *J* = 4.7 Hz, 1H), 3.77 (q, *J* = 7.0 Hz, 1H), 2.76 – 2.61 (m, 2H), 2.58 – 2.47 (m, 3H), 2.43 – 2.31 (m, 2H), 2.24 – 2.17 (m, 1H), 2.12 (s, 3H), 2.09 – 1.99 (m, 2H), 1.87 – 1.85 (m, 1H), 1.80 – 1.71(m, 2H), 1.56 – 1.46 (m, 3H), 1.41 (d, *J* = 7.0 Hz, 3H), 1.07 (d, *J* = 6.0 Hz, 3H), 1.02 (d, *J* = 6.8 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 212.0, 209.0, 208.5, 171.0, 159.4, 140.3, 128.9, 1278, 127.2, 91.2, 57.0, 52.7, 52.0, 41.2, 40.7, 36.3, 35.2, 34.5, 31.0, 29.8, 27.9, 20.4, 20.0, 17.3, 11.4.

NMR data for the product from (*R*)-L:

¹H NMR (400 MHz, CD₂Cl₂) δ 8.04 (s, 1H), 7.34 (t, *J* = 7.4 Hz, 2H), 7.29 – 7.26 (m, 1H), 7.25 – 7.21 (m, 2H), 6.85 (d, *J* = 4.8 Hz, 1H), 3.80 (q, *J* = 7.0 Hz, 1H), 2.79 – 2.71 (m, 1H), 2.66 – 2.54 (m, 2H), 2.52 – 2.29 (m, 4H), 2.19 – 2.13 (m, 1H), 2.08 (s, 3H), 2.06 – 1.99 (m, 2H), 1.87 – 1.85 (m, 1H), 1.79 – 1.65 (m, 2H), 1.53 – 1.45 (m, 3H), 1.39 (d, *J* = 7.0 Hz, 3H), 1.06 (d, *J* = 5.6 Hz, 3H), 1.01 (d, *J* = 6.8 Hz, 3H).

¹³C NMR (101 MHz, CD₂Cl₂) δ 212.3, 208.8, 171.6, 159.9, 141.0, 129.2, 128.3, 127.5, 91.6, 57.3, 52.9, 52.3, 41.5, 41.0, 36.8, 35.7, 34.9, 31.3, 30.0, 28.3, 20.6, 20.4, 17.6, 11.6.

FT-IR (film): 2926, 1759, 1712, 1453, 1374, 1172, 1103, 958, 766, 702 cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₂₇H₃₆O₇Na: 495.2353, found: 495.2350. [α]²⁵_D = +71.1 (*c* 1.0, CH₂Cl₂); 98:2 dr from (*S*)-L. [α]²⁵_D = -71.2 (*c* 1.0, CH₂Cl₂); 1:99 dr from (*R*)-L.



(3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-

epoxy[1,2]dioxepino[4,3-*i***]isochromen-10-yl 5-([1,1'-biphenyl]-4-yl)-4-oxohexanoate** (Fig. 4, **compound 68).** The title compound was synthesized according to **GP-C** from artesunate and 4-ethyl-1,1'-biphenyl. The product was purified by column chromatography on silica gel (1:4 EtOAc/Petroleum ether). White solid (mp = 88-90 °C).

(*S*)-L: 202 mg, 74% yield, 97:3 dr;

(*R*)-L: 202 mg, 74% yield, 5:95 dr.

HPLC analysis: The dr was determined via HPLC on a CHIRALCEL OD-3 column (30.0% 2-PrOH in hexanes, 0.8 mL/min); retention times for compound obtained using (*S*)-L: 12.2 min (major), 25.1 min (minor).

NMR data for the product from (*S*)-L:

¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 7.58 – 7.54 (m, 4H), 7.42 (t, *J* = 7.6 Hz, 2H), 7.35 – 7.31 (m, 1H), 7.28 (s, 2H), 6.89 (d, *J* = 4.9 Hz, 1H), 3.82 (q, *J* = 7.0 Hz, 1H), 2.75 – 2.65 (m, 2H), 2.59 – 2.48 (m, 3H), 2.42 – 2.30 (m, 2H), 2.21 – 2.15 (m, 1H), 2.10 (s, 3H), 2.07 – 1.98 (m, 2H), 1.86 – 1.80 (m, 1H), 1.79 – 1.69 (m, 2H), 1.57 – 1.46 (m, 3H), 1.44 (d, *J* = 7.0 Hz, 3H), 1.05 (d, *J* = 6.0 Hz, 3H), 1.02 (d, *J* = 6.8 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 212.0, 209.0, 208.4, 171.0, 159.4, 140.4, 140.1, 139.2, 128.7, 128.2, 127.6, 127.3, 126.9, 91.2, 56.9, 52.3, 51.9, 41.1, 40.7, 36.3, 35.2, 34.5, 31.0, 29.8, 27.9, 20.4, 20.0, 17.3, 11.4.

NMR data for the product from (*R*)-L:

¹H NMR (400 MHz, CD₂Cl₂) δ 8.04 (s, 1H), 7.60 – 7.57 (m, 4H), 7.43 (t, *J* = 7.3 Hz, 2H), 7.35 (d, *J* = 7.7 Hz, 1H), 7.30 (d, *J* = 7.3 Hz, 2H), 6.86 (d, *J* = 4.2 Hz, 1H), 3.84 (q, *J* = 6.8 Hz, 1H), 2.83 – 2.75 (m, 1H), 2.72 – 2.56 (m, 2H), 2.53 – 2.38 (m, 3H), 2.36 – 2.27 (m, 1H), 2.21 – 2.13 (m, 1H), 2.07 (s, 3H), 2.03 – 1.98 (m, 2H), 1.87 – 1.84 (m, 1H), 1.77 – 1.67 (m, 2H), 1.51 (dd, *J* = 18.7, 9.9 Hz, 3H), δ 1.42 (d, *J* = 7.0 Hz, 3H), 1.05 (d, *J* = 4.5 Hz, 3H), 1.01 (d, *J* = 6.7 Hz, 3H).

¹³C NMR (101 MHz, CD₂Cl₂) δ 212.3, 208.9, 208.8, 171.6, 160.0, 140.9, 140.4, 140.1, 129.2, 128.8, 127.9, 127.8, 127.3, 91.7, 57.4, 52.6, 52.3, 41.5, 41.0, 36.9, 35.8, 34.9, 31.4, 30.0, 28.4, 20.7, 20.5, 17.6, 11.6.

FT-IR (film): 2920, 2850, 1755, 1707, 1485, 1353, 1160, 1100, 954, 766, 698 cm⁻¹. HRMS (ESI-MS) m/z [M+Na]⁺ calcd for C₃₃H₄₀O₇Na: 571.2666, found: 571.2664. [α]²⁵_D = +82.6 (*c* 1.0, CH₂Cl₂); 97:3 dr from (*S*)-L. [α]²⁵_D = -67.2 (*c* 1.0, CH₂Cl₂); 5: 95 dr from (*R*)-L.



(3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-

epoxy[1,2]dioxepino[4,3-*i*]isochromen-10-yl 5-(4-methoxyphenyl)-4-oxohexanoate (Fig. 4, compound 69). The title compound was synthesized according to GP-C from artesunate and 1-ethyl-4-methoxybenzene. The product was purified by column chromatography on silica gel (1:4 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 186 mg, 74% yield, 97:3 dr;

(*R*)-L: 184 mg, 73% yield, 2:98 dr.

HPLC analysis: The dr was determined via HPLC on a CHIRALCEL OD-3 column (30.0% 2-PrOH in hexanes, 0.8 mL/min); retention times for compound obtained using (*S*)-L: 10.3 min (major), 13.1 min (minor).

NMR data for the product from (*S*)-L:

¹H NMR (400 MHz, CD₂Cl₂) δ 8.05 (s, 1H), 7.13 (d, *J* = 8.7 Hz, 2H), 6.88 – 6.84 (m, 3H), 3.78 (s, 3H), 3.73 (q, *J* = 7.0 Hz, 1H), 2.70 – 2.62 (m, 2H), 2.54 – 2.46 (m, 3H), 2.43 – 2.30 (m, 2H), 2.19 – 2.14 (m, 1H), 2.08 (s, 3H), 2.06 – 1.98 (m, 2H), 1.87 – 1.84 (m, 1H), 1.76 – 1.68 (m, 2H), 1.57 – 1.44 (m, 3H), 1.35 (d, *J* = 7.0 Hz, 3H), 1.06 (d, *J* = 6.0 Hz, 3H), 1.00 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (101 MHz, CD₂Cl₂) δ 212.3, 209.1, 208.9, 171.6, 160.0, 159.3, 133.0, 129.3, 114.6, 91.6, 57.4, 55.6, 52.3, 52.1, 41.5, 41.0, 36.8, 35.5, 34.9, 31.4, 30.0, 28.4, 20.7, 20.5, 17.7, 11.6.

NMR data for the product from (*R*)-L:

¹H NMR (400 MHz, CD₂Cl₂) δ 8.03 (s, 1H), 7.12 (d, *J* = 8.6 Hz, 2H), 6.86 – 6.84 (m, 3H), 3.76 (s, 3H), 3.72 (t, *J* = 7.0 Hz, 1H), 2.76 – 2.67 (m, 1H), 2.65 – 2.53 (m, 2H), 2.51 – 2.36 (m, 3H), 2.34 – 2.28 (m, 1H), 2.18 – 2.14 (m, 1H), 2.07 (s, 3H), 2.05 – 1.97 (m, 2H), 1.86 – 1.83 (m, 1H), 1.78 – 1.67 (m, 2H), 1.53 – 1.43 (m, 3H), 1.34 (d, *J* = 7.0 Hz, 3H), 1.05 (d, *J* = 5.7 Hz, 3H), 1.00 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (101 MHz, CD₂Cl₂) δ 212.3, 209.1, 208.9, 171.6, 160.0, 159.2, 132.9, 129.2, 114.6, 91.6, 57.3, 55.6, 52.3, 52.1, 41.5, 41.0, 36.8, 35.5, 34.9, 31.3, 30.0, 28.4, 20.6, 20.4, 17.6, 11.6.

FT-IR (film): 2927, 1755, 1708, 1510, 1444, 1372, 1245, 1177, 1102, 1023, 949, 831 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₂₈H₃₈O₈Na: 525.2459, found: 525.2456.

 $[\alpha]^{25}$ D = +79.2 (*c* 1.0, CH₂Cl₂); 97:3 dr from (*S*)-L.

 $[\alpha]^{25}$ _D = -94.9 (*c* 1.0, CH₂Cl₂); 2:98 dr from (*R*)-L.



(3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-

epoxy[1,2]dioxepino[4,3-*i***]isochromen-10-yl 4-oxo-5-(3-phenoxyphenyl)hexanoate (Fig. 4, compound 70).** The title compound was synthesized according to **GP-C** from artesunate and 1-ethyl-3-phenoxybenzene. The product was purified by column chromatography on silica gel (1:4 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 214 mg, 76% yield, 98:2 dr;

(*R*)-L: 209 mg, 74% yield, 2:98 dr.

HPLC analysis: The dr was determined via HPLC on a CHIRALPAK AD-3 column (40.0% 2-PrOH in hexanes, 0.8 mL/min); retention times for compound obtained using (*S*)-L: 11.3 min (major), 12.9 min (minor).

NMR data for the product from (*S*)-L:

¹H NMR (400 MHz, CD₂Cl₂) δ 8.04 (s, 1H), 7.36 – 7.28 (m, 3H), 7.11 (t, *J* = 7.4 Hz, 1H), 7.01- 6.95 (m, 3H), 6.89 – 6.85 (m, 3H), 3.76 (q, *J* = 7.0 Hz, 1H), 2.76 – 2.67 (m, 2H), 2.53 – 2.47 (m, 3H), 2.46 – 2.37 (m, 1H), 2.36 – 2.29 (m, 1H), 2.19 – 2.15 (m, 1H), 2.07 (s, 3H), 2.05 – 1.98 (m, 2H), 1.85 – 1.81 (m, 1H), 1.77 – 1.68 (m, 2H), 1.56 – 1.42 (m, 3H), 1.36 (d, *J* = 7.0 Hz, 3H), 1.05 (d, *J* = 5.6 Hz, 3H), 1.01 (d, *J* = 6.8 Hz, 3H).

¹³C NMR (101 MHz, CD₂Cl₂) δ 212.3, 208.9, 208.4, 171.5, 159.9, 158.1, 157.4, 143.0, 130.6, 130.2, 123.8, 123.1, 119.3, 118.8, 117.8, 91.6, 57.4, 52.8, 52.3, 41.5, 41.0, 36.9, 35.7, 34.9, 31.4, 30.0, 28.3, 20.7, 20.5, 17.5, 11.6.

NMR data for the product from (*R*)-L:

¹H NMR (400 MHz, CD₂Cl₂) δ 8.04 (s, 1H), 7.36 – 7.27 (m, 3H), 7.11 (t, *J* = 7.4 Hz, 1H), 7.00 – 6.95 (m, 3H), 6.89 – 6.85 (m, 3H), 3.77 (q, *J* = 6.8 Hz, 1H), 2.77 – 2.71 (m, 1H), 2.69 – 2.54 (m, 2H), 2.53 – 2.38 (m, 3H), 2.36 – 2.28 (m, 1H), 2.20 – 2.15 (m, *J* = 6.8 Hz, 1H), 2.07 (s, 3H), 2.03 – 1.99 (m, 2H), 1.86 – 1.84 (m, 1H), 1.79 – 1.67 (m, 2H), 1.54 – 1.44 (m, 3H), 1.37 (d, *J* = 6.9 Hz, 3H), 1.05 (d, *J* = 5.3 Hz, 3H), 1.01 (d, *J* = 6.8 Hz, 3H).

¹³C NMR (101 MHz, CD₂Cl₂) δ 212.3, 208.9, 208.5, 171.6, 160.0, 158.1, 157.4, 143.0, 130.6, 130.2, 123.8, 123.1, 119.3, 118.7, 117.7, 91.7, 57.3, 52.8, 52.3, 41.5, 41.0, 36.9, 35.7, 34.9, 31.4, 30.0, 28.4, 20.7, 20.5, 17.5, 11.6.

FT-IR (film): 2929, 1759, 1712, 1581, 1485, 1375, 1244, 1165, 1105, 952, 757, 694 cm⁻¹.

HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₃₃H₄₀O₈Na: 587.2615, found: 587.2613.

 $[\alpha]^{25}$ D = +68.8 (*c* 1.0, CH₂Cl₂); 98:2 dr from (*S*)-L.

 $[\alpha]^{25_{\rm D}} = -117.2$ (*c* 1.0, CH₂Cl₂); 2:98 dr from (*R*)-L.

V. Mechanistic Studies

A. Kinetic isotope effect experiments

Parallel reactions:



Supplementary Figure 2.

Given the reaction mixture of the enantioselective benzylic C(sp³)–H acylation is heterogeneous, the reactions were carried out based on the standard conditions at various time independently.

The procedure is the same as **GP-B**, except for the following changes: the dodecane (110 μ L, 0.50 mmol) was added as an internal standard. The reaction was stirred under blue LEDs irradiation for the indicated time. All the reactions were quenched through a small plug of silica gel, which was flushed with Et₂O. The yield was determined via GC analysis with dodecane as an internal standard (see Supplementary Figure 3 & 4). A primary kinetic isotope effect (KIE = 0.1302/0.0639 = 2.0) was obtained by parallel reactions.



Supplementary Figure 3.



Supplementary Figure 4.

Competition reactions:



Supplementary Figure 5.

The procedure is the same as **GP-A**, and the reactions were stirred under blue LEDs irradiation for 40 min and 200 min, respectively. All the reactions were quenched through a small plug of silica gel, which was flushed with Et₂O. The yield was determined via GC analysis with dodecane as an internal standard. The remainder of the filtrate was concentrated via rotary evaporation, and the pure product was isolated by preparative thin-layer chromatography on silica gel (1:40 EtOAc/hexanes) to give the mixture of **1** and **1-d** as a white solid.

The KIE ratio was determined by quantitative ¹H-NMR spectroscopy (see Supplementary Figure 6).

First run: KIE = 2.4 (6% yield); second run: KIE = 2.3 (39% yield).





B. Benzylic radical trapping experiments



Supplementary Figure 7.

The procedure is the same as **GP-A**, except for the following changes: a solution of the methyl 2-((phenylsulfonyl)methyl)acrylate (24.0 mg, 1.0 M solution in *i*-PrOAc, 0.10 mmol, 1.0 equiv) was added via a 250 µL microsyringe.



Mthyl 4-([1,1'-biphenyl]-4-yl)-2-methylenepentanoate (Fig. 5, compound 71). The title compound was synthesized according to **GP-A** from 4-ethylbiphenyl and methyl 2-((phenylsulfonyl)methyl)acrylate. The pure product was isolated by preparative thin-layer chromatography on silica gel (1: 25 EtOAc/hexanes) to give a white solid (16.1 mg, 58% yield).

¹H NMR (500 MHz, CDCl₃) δ 7.60 – 7.57 (m, 2H), 7.54 – 7.52 (m, 2H), 7.45 – 7.40 (m, 2H), 7.35 – 7.31 (m, 1H), 7.28 – 7.27 (m, 1H), 6.13 (d, *J* = 1.5 Hz, 1H), 5.42 (d, *J* = 1.4 Hz, 1H), 3.74 (s, 3H), 3.07 – 3.30 (m, 1H), 2.69 – 2.64 (m, 1H), 2.59 – 2.54 (m, 1H), 1.30 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 167.7, 145.6, 141.0, 139.0, 138.8, 128.7, 127.5, 127.0, 126.99, 126.96, 126.7, 51.8, 40.9, 38.4, 21.3.

FT-IR (film): 3027, 2958, 1719, 1629, 1486, 1438, 1304, 1201, 1150, 947, 838, 765, 697 cm⁻¹. HRMS (ESI-MS) *m*/*z* [M+Na]⁺ calcd for C₁₉H₂₀O₂Na: 303.1356, found: 303.1353.



In a glovebox, Ir[dF(CF₃)ppy]₂(dtbbpy)PF₆ (1.1 mg, 0.001 mmol, 1%), NaBr (15.4 mg, 0.15 mmol, 1.5 equiv), Na₂HPO₄ (21.3 mg, 0.15 mmol, 1.5 equiv), a Teflon stir bar, and anhydrous *i*-PrOAc (1.0 mL) were added sequentially to a 4 mL vial. Next, a solution of the 4-ethylbiphenyl (150 µL, 2.0 M solution in *i*-PrOAc, 0.30 mmol, 3.0 equiv) was added via a 250 µL microsyringe. The vial was sealed with a septum cap and wrapped with electrical tape. Then, a solution of the methyl 2-((phenylsulfonyl)methyl)acrylate (100 µL, 24.0 mg, 1.0 M solution in *i*-PrOAc, 0.10 mmol, 1.0 equiv) was added via a 100 µL microsyringe. Next, the vial was transferred out of the glovebox, and then vacuum grease was liberally applied to cover the entire top of the septum cap. Then, the reaction mixture was stirred at 10 °C in an EtOH bath for 5 min before being irradiated with a 40 W blue LED lamp (Kessil PR160L, 427 nm). The reaction was stirred under irradiation at 10 °C for 25 hours. Next, the lamp was turned off and the resulting mixture was allowed to warm to room temperature, and then dodecane (22 µL, 0.10 mmol) was added as an internal standard. The mixture was filtered through a small plug of silica gel, which was flushed with Et₂O (~6 mL). A portion of the filtrate (~0.1 mL) was diluted with acetone (total volume: ~1 mL) and analyzed via GC, and the remainder of the filtrate was concentrated via rotary evaporation, and the pure product was isolated by preparative TLC on silica gel (1:25 EtOAc/hexanes). The yield was determined via GC analysis with dodecane as an internal standard.

VI. Assignment of Absolute Configuration

The configuration of the coupling product **59** illustrated in Figure 3 prepared with (*R*)-L, was determined via X-ray crystallography.



Supplementary Figure 8. Thermal ellipsoid plot at the 50% probability level.



(*R*)-3-([1,1'-Biphenyl]-4-yl)-1-(2,4-dichlorophenoxy)butan-2-one. X-ray quality crystals were obtained by slow evaporation of a saturated solution in hexane and *i*-PrOH of a sample synthesized using (*R*)-L. All measurements were made on a 'Bruker APEX-II CCD' diffractometer with filtered Cu-K α radiation at a temperature of 293 K. Using Olex2, the structure was solved with the ShelXT structure solution program using direct methods and refined with the ShelXL refinement package using least squares minimization.^{2,3} The absolute stereochemistry was determined on the basis of the absolute structure parameter.

Identification code	Compound 59
Empirical formula	C22H18Cl2O2
Formula weight	385.29
Temperature	150.00(10) K
Wavelength	1.54184 Å
Crystal system	orthorhombic
Space group	$P2_{1}2_{1}2_{1}$
Unit cell dimensions	$a = 5.37670(10) \text{ Å} \qquad \alpha = 90^{\circ}$
	$b = 8.17780(10) \text{ Å} \qquad \beta = 90^{\circ}$
	$c = 41.0081(5) \text{ Å} \qquad \gamma = 90^{\circ}$
Volume	1803.11(5) Å ³
Z	4
Density (calculated)	1.4192 g/cm ³
Absorption coefficient	3.345 mm ⁻¹
F(000)	805.0
Theta range for data collection	8.62 to 143.06°.
Index ranges	$-3 \leq h \leq 6, \ -9 \leq k \leq 9, \ -49 \leq l \leq 49$
Reflections collected	15998
Independent reflections	3388 [R(int) = 0.0443, R(sigma) = 0.0320]
Data / restraints / parameters	3388 / 0 / 236
Goodness-of-fit on F ²	1.042
Final R indices [I>2sigma(I)]	R1 = 0.0292, $wR2 = 0.0760$
R indices (all data)	R1 = 0.0304, wR2 = 0.0767
Absolute structure parameter [Flack]	-0.010(11)
Largest diff. peak and hole	0.17 and -0.19 e.Å ⁻³

Supplementary Table 2. Crystal data and structure refinement for the product 59.

The configuration of the coupling product **20** illustrated in **Fig. 2** was determined via comparison of optical rotation with the literature.



(*R*)-1,4-Diphenylpentan-3-one (20). $[\alpha]^{25_D} = -142.5$ (*c* 1.0, CH₂Cl₂); 93% ee from (*R*)-L. Lit for **R** isomer: $[\alpha]^{26_D} = -407.4$ (*c* 0.2, CH₂Cl₂, 90% ee).⁴

The configuration of the coupling product **75** illustrated in **Fig. 6** was determined via comparison of optical rotation with the literature.



Phenyl (S)-2-phenylpropanoate (75). $[\alpha]^{25}D = +74.4$ (*c* 1.0, CHCl₃); 83% ee from (*S*, *R*)-L. Lit for *R*-isomer: $[\alpha]^{20}D = +85.3$ (*c* 1.4, CHCl₃, 92% ee).⁵



VII. ¹H-NMR and ¹³C-NMR Spectra; Stereoselectivity Analysis





S-59















S-62





230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 Supplementary Figure 15. ¹H NMR and ¹³C NMR spectrum of 7.







Supplementary Figure 16. ¹H NMR and ¹³C NMR spectrum of 8.







20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -2. fl (ppm)

Supplementary Figure 18. ¹⁹F NMR spectrum of 9.







210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm) Supplementary Figure 19. ¹H NMR and ¹³C NMR spectrum of 10.







220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 f1 (ppm) Supplementary Figure 20. ¹H NMR and ¹³C NMR spectrum of 11.





Supplementary Figure 22. ¹H NMR and ¹³C NMR spectrum of 13.



S-71





Supplementary Figure 24. ¹H NMR and ¹³C NMR spectrum of 15.
$\begin{array}{c} & 7.56 \\ & 7.58 \\ & 7.58 \\ & 7.58 \\ & 7.58 \\ & 7.57 \\ & 7.57 \\ & 7.57 \\ & 7.57 \\ & 7.57 \\ & 7.57 \\ & 7.56 \\ & 7.56 \\ & 7.73 \\ & 7.73 \\ & 7.73 \\ & 7.73 \\ & 7.73 \\ & 7.73 \\ & 7.73 \\ & 7.73 \\ & 7.73 \\ & 7.73 \\ & 7.73 \\ & 7.73 \\ & 7.73 \\ & 7.73 \\ & 7.75 \\ & 7.74 \\ & 7.75 \\ & 7.$





Supplementary Figure 25. ¹H NMR and ¹³C NMR spectrum of 16.



8.8.8 8.10 8.00 8.00 8.00 8.00 9.000 9.0000 9.0000 9.0000 9.0000 9.0000 9.0000 9.0000 9.0000 9.0000 9.0000 9.0000 9.0000 9.00000 9.0000 9.00000 9.00000 9.000000 9.0000000000				CDCI3
	8.56 8.10 8.09 8.07 8.07 8.07 7.96 7.96 7.94 7.87 7.85 7.85	7.82 7.57 7.57 7.57 7.55 7.55 7.55 7.55 7.5	7.53 7.53 7.52 7.52 7.47 7.47 7.45 7.43 7.43 7.41 7.41 7.41	7.34 7.32 7.32 7.26 7.26 7.32 7.32 7.32 7.32 7.32 7.32 7.32 7.32



Fig. 2. (18)



Supplementary Figure 27. ¹H NMR and ¹³C NMR spectrum of 18.





220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 f1 (ppm) Supplementary Figure 28. ¹H NMR and ¹³C NMR spectrum of 19.









Supplementary Figure 31. ¹H NMR and ¹³C NMR spectrum of 21.







Supplementary Figure 33. ¹H NMR and ¹³C NMR spectrum of 23.



Supplementary Figure 34. ¹H NMR and ¹³C NMR spectrum of 24.









Supplementary Figure 37. ¹H NMR and ¹³C NMR spectrum of 26.



Supplementary Figure 38. ¹H NMR and ¹³C NMR spectrum of 27.





Supplementary Figure 39. ¹H NMR and ¹³C NMR spectrum of 28.





Supplementary Figure 40. ¹H NMR and ¹³C NMR spectrum of **29**.



Supplementary Figure 41. ¹H NMR and ¹³C NMR spectrum of 30.













Supplementary Figure 44. ¹H NMR and ¹³C NMR spectrum of 32.



Supplementary Figure 45. ¹H NMR and ¹³C NMR spectrum of 33.









Supplementary Figure 47. ¹H NMR and ¹³C NMR spectrum of 35.















Supplementary Figure 50. ¹H NMR and ¹³C NMR spectrum of 38.



Supplementary Figure 51. ¹H NMR and ¹³C NMR spectrum of 39.





Fig. 2. (40)





Supplementary Figure 53. ¹H NMR and ¹³C NMR spectrum of 41.



Supplementary Figure 54. ¹H NMR and ¹³C NMR spectrum of 42.





Fig. 2. (43)







Fig. 2. (44)



Supplementary Figure 56. ¹H NMR and ¹³C NMR spectrum of 44.





Fig. 2. (45)





Supplementary Figure 58. ¹H NMR and ¹³C NMR spectrum of 46.





7,40 7,7,33 7,7,33 7,7,33 7,7,33 7,7,33 7,7,33 7,7,33 7,7,23 7,7,137,7,13



Fig. 3. (48)




S-109



Fig. 3. (50)







Supplementary Figure 63. ¹H NMR and ¹³C NMR spectrum of 51.







Supplementary Figure 64. ¹H NMR and ¹³C NMR spectrum of 52.



Supplementary Figure 65. ¹H NMR and ¹³C NMR spectrum of 53.



Supplementary Figure 66. ¹H NMR and ¹³C NMR spectrum of 54.



Supplementary Figure 67. ¹H NMR and ¹³C NMR spectrum of 55.



Supplementary Figure 68. ¹H NMR and ¹³C NMR spectrum of 56.



Supplementary Figure 69. ¹H NMR and ¹³C NMR spectrum of 57.



Supplementary Figure 70. ¹H NMR and ¹³C NMR spectrum of 58.







Supplementary Figure 72. ¹H NMR and ¹³C NMR spectrum of 60.

 $\begin{array}{c} 7.50\\ 7.57\\ 7.57\\ 7.57\\ 7.75\\ 7.75\\ 7.75\\ 7.75\\ 7.75\\ 7.75\\ 7.75\\ 7.75\\ 3.36\\ 0.33\\ 3.82\\ 3.3.82\\ 3.3.82\\ 3.3.82\\ 3.3.82\\ 1.90\\ 1.90\\ 1.10\\ 1.12\\ 1.1$



Supplementary Figure 73. ¹H NMR and ¹³C NMR spectrum of 61.



Supplementary Figure 74. ¹H NMR and ¹³C NMR spectrum of 62.



20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -2 fl (ppm)

Supplementary Figure 75. ¹⁹F NMR spectrum of 62.



F Me

Fig. 4. (63)



Supplementary Figure 76. ¹H NMR and ¹³C NMR spectrum of 63.







Fig. 4. (64)

Supplementary Figure 78. ¹H NMR and ¹³C NMR spectrum of 64.

Supplementary Figure 79. ¹⁹F NMR spectrum of 64.

Fig. 4. (65)

Supplementary Figure 80. ¹H NMR and ¹³C NMR spectrum of 65.

Supplementary Figure 81. ¹⁹F NMR spectrum of 65.

S-130

Supplementary Figure 83. ¹⁹F NMR spectrum of 66.

Fig. 4. (67-a)

Supplementary Figure 84. ¹H NMR and ¹³C NMR spectrum of 67-a.

Supplementary Figure 85. ¹H NMR and ¹³C NMR spectrum of 67-b.

8.04 7.58 7.55 7.55 7.55 7.55 7.55 7.55 7.55 7.55 7.44 7.42 7.42 7.42 7.55 7.74 7.42 7.55 7.72 7.28 7.72 7.28 7.29 7.28 7.29 7.29 7.29 7.29 7.29 7.29 7.29 7.29 7.29 7.29

Supplementary Figure 86. ¹H NMR and ¹³C NMR spectrum of 68-a.

 8.04

 7.50

 7.560

 7.58

 7.58

 7.58

 7.58

 7.58

 7.58

 7.57

 7.58

 7.58

 7.58

 7.58

 7.58

 7.58

 7.58

 7.58

 7.58

 7.58

 7.58

 7.58

 7.42

 7.42

 7.42

 7.42

 7.53

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

 6.87

<

Supplementary Figure 88. ¹H NMR and ¹³C NMR spectrum of 69-a.

803 7.13 6.86 6.86 6.86 6.86 6.85 6.85 6.85 6.85 6.85 6.85 6.85 6.85 6.85 6.85 6.85 2.37 2.65 2.17 2

0.0

Supplementary Figure 90. ¹H NMR and ¹³C NMR spectrum of 70-a.

Supplementary Figure 91. ¹H NMR and ¹³C NMR spectrum of 70-b.

S-140

Supplementary Figure 93. ¹H NMR and ¹³C NMR spectrum of 72.

7.64 7.64 7.65 7.65 7.65 7.65 7.65 7.65 7.65 7.65		6	ר ר	
7.64 7.64 7.65 7.65 7.65 7.62 7.75 7.75 7.75 7.75 7.75 7.75 7.73 7.73		7	-	
7.64 7.62 7.62 7.62 7.62 7.62 7.62 7.62 7.62				
7.64 7.64 7.65 7.65 7.65 7.65 7.75 7.65 7.75 7.65 7.75 7.7		Č	`	
7.64 7.64 7.65 7.62 7.62 7.62 7.62 7.62 7.62 7.62 7.62			-	
$\begin{array}{c} 7.64\\ 1.62\\$		(
7.64 7.51 7.52 7.52 7.52 7.54 7.54 7.54 7.54 7.54 7.54 7.54 7.55 7.55				
0 0 0 0 0 0 0 0 0 0 0 0 0 0	44000-0000	x r v v 6 6 x r 9 9 v v v v v) 4 0 - v 4 0 x 0 - v	0 6 8 7 0 6 8 9 8 9 9
	000000044	* 4 4 4 0 0 0 0 0 0 0 0 0 0 0	1 A A A O O A A A A	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
<u> </u>				
	~~~~~~			

![](_page_141_Figure_1.jpeg)

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm) Supplementary Figure 94. ¹H NMR and ¹³C NMR spectrum of 73.

![](_page_142_Figure_0.jpeg)

Supplementary Figure 95. ¹H NMR and ¹³C NMR spectrum of 74.

![](_page_143_Figure_0.jpeg)

Supplementary Figure 96. ¹H NMR and ¹³C NMR spectrum of 75.
## **Stereoselectivity Analysis**



(S)-L: 94% ee; (R)-L: 94% ee.





(S)-L: 95% ee; (R)-L: 95% ee.





(S)-L: 94% ee; (R)-L: 94% ee.





(S)-L: 93% ee; (R-L: 94% ee.





(S)-L: 95% ee; (R)-L: 95% ee.





(S)-L: 92% ee; (R)-L: 93% ee.





(S)-L: 93% ee; (R)-L: 93% ee.







Supplementary Figure 104. HPLC data of 8.



(S)-L: 95% ee; (R)-L: 97% ee.





(S)-L: 94% ee; (R)-L: 93% ee.





(S)-L: 94% ee; (R)-L: 94% ee. DAD1D, Sig=254, 4 Ref=380, 60 200-175-150-125 0 120-N₩ 100-75-557 50-**-**14. 25-0-1 ż 3 5 6 ż 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 4 Ŕ ġ Time [min] Signal: DAD1D, Sig=254, 4 Ref=380, 60 RetTime Width Height Area Area Туре [mAU] [min] [min] [mAU*s] % 14.557 VV 0.50003 93.51496 7.11298 2.7948 0.92224 200.32318 97.2052 15.641 3252.48375 VV Totals 3345.99872 DAD1D, Sig=254, 4 Ref=380, 60 250 20 Æ 200 150ШAU 100-**←**15.255 50 0-10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 ż ż 5 8 ģ 1 4 6 Ż Time [min] Signal: DAD1D, Sig=254, 4 Ref=380, 60 RetTime Width Area Height Area Type [min] [min] [mAU*s] [mAU] % 14.182 VV 0.76059 3296.73383 241.25052 97.1733 15.255 VV 0.68628 95.90095 6.17637 2.8267 Totals 3392.63478

Supplementary Figure 107. HPLC data of 11.



(S)-L: 92% ee; (R)-L: 93% ee.





(S)-L: 95% ee; (R)-L: 95% ee.









Supplementary Figure 110. HPLC data of 14.



(S)-L: 93% ee; (R)-L: 93% ee.





(S)-L: 94% ee; (R)-L: 93% ee.









Fig. 2. (18)

(*S*, *R*)-L: 69% ee; (*R*, *S*)-L: 71% ee.











(S)-L: 93% ee; (R)-L: 93% ee





(S)-L: 95% ee; (R)-L: 95% ee.





(S)-L: 97% ee; (R)-L: 97% ee.





(S)-L: 95% ee; (R)-L: 95% ee.





(S)-L: 93% ee; (R)-L: 93% ee.









(S)-L: 92% ee; (R)-L: 90% ee.









(S)-L: 93% ee; (R)-L: 95% ee.





(S)-L: 95% ee; (R)-L: 94% ee.





(S)-L: 93% ee; (R)-L: 93% ee.





(S)-L: 93% ee; (R)-L: 93% ee.





(S)-L: 93% ee; (R)-L: 94% ee.





(S)-L: 91% ee; (R)-L: 90% ee.











(S)-L: 95% ee; (R)-L: 94% ee.





(S)-L: 86% ee; (R)-L: 86% ee.




(S)-L: 94% ee; (R)-L: 94% ee.





(S)-L: 94% ee; (R)-L: 94% ee





(S)-L: 93% ee; (R)-L: 93% ee.





(S)-L: 95% ee; (R)-L: 94% ee.





(S)-L: 95% ee; (R)-L: 95% ee.





(S)-L: 95% ee; (R)-L: 93% ee.





(S)-L: 80% ee; (R)-L: 83% ee.





(S)-L: 94% ee; (R)-L: 95% ee.





(S)-L: 82% ee; (R)-L: 81% ee.





(S)-L: 95% ee; (R)-L: 95% ee.





(S)-L: 94% ee; (R)-L: 95% ee.





(S)-L: 93% ee; (R)-L: 94% ee.





(S)-L: 94% ee; (R)-L: 93% ee.





(S)-L: 93% ee; (R)-L: 92% ee.





(S)-L: 92% ee; (R)-L: 92% ee.





(S)-L: 4:96 dr; (R)-L: 96:4 dr.





(S)-L: 3:97 dr; (R)-L: 99:1 dr.





Supplementary Figure 150. HPLC data of 56.



(S)-L: 90% ee; (R)-L: 90% ee.





(S)-L: 94% ee; (R)-L: 94% ee.





(S)-L: 87% ee; (R)-L: 86% ee.



Supplementary Figure 153. HPLC data of 59.



Supplementary Figure 154. HPLC data of 60 & 61.



(S)-L: 94% ee; (R)-L: 94% ee.





(S)-L: 91% ee; (R)-L: 92% ee.











(S)-L: 90% ee; (R)-L: 90% ee.











(S)-L: 98:2 dr; (R)-L: 1:99 dr.





Supplementary Figure 161. HPLC data of 68.





Supplementary Figure 163. HPLC data of 70.



(S, R)-L: 98% ee; (R, S)-L: 98% ee.





















## **VIII.** Supplementary References

1. Zhang, W. et al. Enantioselective cyanation of benzylic C–H bonds via copper-catalyzed radical relay. *Science* **353**, 1014–1018 (2016).

2. a) Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. OLEX2: a complete structure solution, refinement and analysis program. *J. Appl. Cryst.* **42**, 339–341 (2009). b) Bourhis, L. J., Dolomanov, O. V., Gildea, R. J., Howard, J, A. K. & Puschmann, H. The anatomy of a comprehensive constrained, restrained refinement program for the modern computing environment-Olex2 dissected. *Acta Cryst.* **A71**, 59–75 (2015).

3. Sheldrick, G. M. SHELXT-Integrated space-group and crystal-structure determination. *Acta Cryst.* **A71**, 3–8 (2015).

4. Gandolfo, E., Tang, X., Raha, R. S. & Melchiorre, P. Photochemical asymmetric nickelcatalyzed acyl cross-coupling. *Angew. Chem. Int. Ed.* **58**, 16854–16858 (2019).

5. Mao, J. et al. Cobalt-bisoxazoline-catalyzed asymmetric Kumada cross-coupling of racemic α-bromo esters with aryl Grignard reagents. *J. Am. Chem. Soc.* **136**, 17662–17668 (2014).